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RATIONALE: Long-acting slow effective release antiretroviral therapy (LASER ART) was 
developed to improve patient regimen adherence, prevent new infections, and facilitate drug 
delivery to human immunodeficiency virus cell and tissue reservoirs. However, maintenance of 
sustained plasma drug levels, for weeks or months, after a single high-level dosing, could improve 
regimen adherence but, at the same time, affect systemic toxicities. Of these, the most troubling are 
those that affect the central nervous system (CNS) In an effort to facilitate LASER ART 
development, “multimodal imaging theranostic nanoprobes” were created. These allow combined 
bioimaging, drug pharmacokinetics and tissue biodistribution tests in animal models. Additionally, 
dolutegravir (Tivicay, DTG), in both a native drug form and within a nanoformulations, were 
administered to mice to investigate potential neurotoxicity or lack thereof in animal models for 
further LASER ART technology development.  
METHODS: Europium (Eu3+)- doped cobalt ferrite (CF) dolutegravir (DTG)- loaded (EuCF-DTG) 
nanoparticles were synthesized then fully characterized based on their size, shape and stability. 
These were then used as platforms for nanoformulated drug biodistribution. Rodents were 
administered parenteral 45-mg/kg doses. DTG-associated changes in CNS homeostasis were 
assessed by measuring brain metabolic activities. After antiretroviral treatment, brain subregions 
were dissected and screened by mass spectrometry-based metabolomics. 
RESULTS: Folic acid (FA) decoration of EuCF-DTG (FA-EuCF-DTG) nanoparticles facilitated 
macrophage targeting and sped drug entry across cell barriers. Macrophage uptake was higher for 
FA-EuCF-DTG than EuCF-DTG nanoparticles with relaxivities of r2 = 546 mM-1 s-1 and r2 = 564 
mM-1 s-1 in saline, and r2 = 850 mM-1 s-1 and r2 = mM-1 s-1 in cells, respectively. The values were 
ten or more times higher than what was observed for ultra-small superparamagnetic iron oxide 
particles (r2 = 31.15 mM-1 s-1 in saline) using identical iron concentrations. Drug particles were 




elicited sustained antiretroviral responses. After parenteral injection of FA-EuCF-DTG and EuCF-
DTG into rats and rhesus macaques, drug, iron and cobalt levels, measured by LC-MS/MS, 
magnetic resonance imaging, and ICP-MS were coordinate. Within metabolomic experimentations, 
metabolic drug-related dysregulation of energy and oxidative stress were readily observed within 
the cerebellum and frontal cortex following native drug administrations. Each was associated with 
alterations in neural homeostasis and depleted canonical oxidation protection pools that included 
glutathione and ascorbic acid. Surprisingly, the oxidative stress-related metabolites were 
completely attenuated when DTG was administered as nanoformulations. These data demonstrate 
the importance of formulation design in control of DTG or perhaps other antiretroviral drug-










































1.1 Global significance of HIV-1  
Human Immunodeficiency Virus (HIV-1) is a progressive retrovirus of the human immune 
system which, if left untreated, can eventually lead to acquired immunodeficiency syndrome 
(AIDS).  Causing a global pandemic shortly after its discovery in the early 1980’s, HIV-1 has been 
in the crosshairs of medical research for several decades, with the molecular structure, function, 
regulation, tropism, and means of viral persistence having now been documented [1-3]. Regardless 
of such efforts, more than 70 million people have been infected with HIV-1 since its discovery, 
with 35 million people succumbing to the virus after initial infection [4]. Additionally, it is 
estimated that at the end of 2017 approximately 37 million people live infected with HIV-1 around 
the world. Treatment and management of patients infected with the virus continues to be one of the 
greatest challenges of the modern medical era. 
Development of treatment options for patients infected with HIV-1 is arguably one of the 
most significant victories in pharmaceutical research, with dozens of effective antiretroviral 
therapies being brought to market since azidothymidine (AZT) was first approved in 1987 [5, 6]. 
Antiretroviral therapy (ART) has allowed for a completely new prognosis following HIV-1 
infection; recently diagnosed patients no longer fear certain death within years but instead 
anticipate a prolonged lifespan with a chronic but manageable disease. Furthermore, more recent 
innovations in ART technology has allowed concurrent administration of multiple antiretroviral 
compounds to patients, drastically increasing their effectiveness in limiting HIV-1 replication and 
inhibiting viral resistance. Combination ART (cART) markedly reduces HIV-1 replication such 
that HIV-1 RNA is undetectable within plasma, allowing for reduced disease morbidity [7, 8]. 
However, despite such pharmacological advances and sustained viral suppression, ART cannot 
eliminate viral infection. Complete viral eradication requires the development of new and novel 





1.2 HIV-1 virology and pathology  
HIV-1 is a retrovirus, using its own reverse transcriptase to transcribe a single stranded 
viral RNA into a double stranded DNA for integration into the host genome and completion of the 
viral life cycle. Two identical copies of single stranded RNA reside within the cylindrical capsid 
of the virus and contain genes needed for the encoding the structural viral proteins [1, 9]. Group-
specific antigen, or gag, encodes the proteins of the viral core and matrix, such as viral capsid 
protein HIV-1 p24 and matrix protein HIV-1p17 [10]. The env gene encodes proteins that form the 
viral envelope, specifically glycoprotein 120 (HIV-1gp120) and transmembrane glycoprotein 41 
(HIV-1gp41). The pol gene encodes a variety of HIV-1 enzymes, such as reverse transcriptase that 
is required for the transcription of HIV-1 RNA into DNA for integration into the host cell genome 
[11]. All three genes are critical for the propagation of HIV-1 within an infected host, and as such 
these genes and the proteins they encode have become biological targets of antiretroviral drug 
(ARV) therapy.  
Protease, ribonuclease, and integrase are also enzymes residing within the HIV-1 core 
encoded by pol that are necessary for HIV-1 replication [12, 13]. In addition to these enzymes, 
several accessory and immune-regulatory genes within the viral capsid core play a vital role for 
viral function. Trans-activator of transcription, or Tat, causes substantially increased levels of 
reverse transcription to occur after a small number of RNA transcripts are made via a positive 
feedback loop [10].  Regulator of viral protein expression, or Rev, dictates the movement of RNA 
from cytoplasm to nucleus. Other necessary proteins include viral protein R (Vpr), viral infectivity 
factor (Vif), negative regulatory factor (Nef), and HIV-1p7 [14]. While the biological mechanism 
in which Vpr, Vif, and Nef influence HIV-1 replication are not completely known, it has been 
established that these proteins positively affect HIV-1 replication.  
The primary target of progeny infectious HIV-1 and the most commonly infected cell is 




of the viral genome in HIV-1 infected patients [17, 18]. These investigations definitively showed 
that  proviral DNA is integrated within CD4+ T cells and to more limited degree monocyte-
macrophages [19]. Indeed, impaired immune response is characteristic of all stages of the disease 
with parallel deficits in numbers and function [20]. Infection of a CD4+ T cells begins when an 
HIV-1 virion encounters its  cluster designation 4 (CD4) receptor together with its co-receptor 
molecule, the C-X-C chemokine receptor type 4 (CXCR4). Co-receptor use ensures viral cell entry. 
Tight binding of HIV-1 gp120 to the CD4 molecule(s) on the surface of the host cell allows the 
membranes of the virus and the host cell to fuse. The virion’s RNA, proteins, and enzymes are then 
released into the cell following successful cellular fusion and digestion of the protective virion 
capsid, with the envelope of HIV-1 remaining on the outer membrane of the cell. 
Reverse transcription is completed by HIV-1 enzymes utilizing the infected host cell’s 
deoxynucleotides. Viral DNA synthesis occurs concurrently with the degradation of the original 
viral RNA, as the reverse transcriptase enzyme also has RNase activity. During each iteration of 
RNA to DNA reverse transcription within a infected host cell, the probability of a random mutation 
is relatively high due to reverse transcriptase’s relatively poor proof reading capabilities [21]. This 
is what allows HIV-1 to develop viral mutations over time that potentially is beneficial to its 
propagation within the host, such as developing ART resistance. Reverse transcription is performed 
twice to produce a double stranded DNA molecule, after which there is binding to the viral integrase 
enzyme. Integrase can then transport the double stranded viral DNA into the nucleus of the host 
cell as well as creating a cut within the host cell genome for viral DNA integration [22].  
DNA replication, RNA transcription, and protein translation occurring via host cell 
machinery allows for the production of progeny HIV-1 that occurs after assembly of viral proteins 
with subsequent transport to the host cell membrane for virion packaging. Assembly is controlled 
primarily by Gag precursor molecules, Pr55 Gag and Pr160 GagPol [23]. The production of a 




particles from the infected cells, and finally proteolytic processing of Pr160 and Pr55 during 
maturation [23].   
1.3 Viral transmission 
Transmission occurs by separate routes (through contaminated needles, by transfusion of 
blood and blood products, from mother to fetus and by receptive anal or vaginal intercourse) [24]. 
The actual process ensues through cells or by the virus itself.  As per the latter, HIV-1 is released 
to float freely within plasma until they come in contact and interact with a host cell suitable for 
entrance and infection. “Cell-to-cell transmission” is the alternative mechanism for the progression 
of HIV-1 infection, in which direct contact between an infected cell with an uninfected naïve cell 
results in HIV-1 transmission. Cell-to-cell transmission occurs during the fusion of HIV-1 infected 
cells with that of uninfected susceptible cells; the fusion process causes the viral components to be 
deposited into the uninfected cell, subsequently causing multinucleated giant cells [25, 26].  
1.4 Immune Response to HIV-1 
AIDS occurs as a consequence of progressive viral infection and CD4+ T cell depletion.  
It is classified as patients infected with HIV-1 that have CD4+ T cell counts below 200 per µl, 
compromising cell-mediated immunity, or by opportunistic viral, fungal, parasitic and 
mycobacterial infections that are strongly associated with advanced HIV-1 infection [14, 27]. 
Ultimately, patients succumb to HIV-1 not directly from the virus itself, but rather indirectly as 
opportunistic infections take advantage of a weakened and dysfunctional immune system. 
However, the progression of the HIV-1 disease state, from initial infection/transmission to 
complete immune failure, is a process taking many years or even decades, and is characterized into 
several distinct stages defined by the current immune response [28]. These four stages are: primary 
infection, a clinically asymptotic period, symptomatic HIV-1 infection, and HIV-1 to AIDS 




each stage; it is of importance to mention that patients consistently taking ARV medication 
generally will not progress to the later stages of the disease [28].  
Primary infection is the beginning of HIV-1 disease progression as the virus establishes 
itself within the host body. This stage typically lasts only a few weeks after initial transmission. 
Within the first 24 hours after infection, HIV-1 virions infect dendritic cells within the mucous 
membrane; after about 5 days, these infected dendritic cells are recruited to lymph nodes and the 
peripheral blood, where replication rates dramatically increase. The primary infection stage is 
characterized by substantially decreasing CD4+ T cells and exponentially increasing levels of 
viremia, often millions of virus copies per milliliter of plasma [29]. Such a large number of HIV-1 
viral particles within the blood allows for systemic infection of peripheral lymphoid organs. 
Regardless of this viral spike, the body’s immune response during primary infection eventually 
results in reduction of virus levels within the peripheral blood. Virus specific cytolytic T 
lymphocytes (CTLs) appear early in infection and potentially downregulate HIV-1 replication [30, 
31]. CD8+ T cells are also credited in controlling the initial viremia peak that is characteristic of 
primary infection; activated and mature CD8+ T cells possess different anti-HIV-1 processes. 
Specifically, CD8+ T-cells can release cytokines such as RANTES, MIP-1 alpha, and MIP-1 beta 
that can effectively block the entry of HIV-1 into host cells by competing for or downregulating 
cellular co-receptor CCR5 [30, 31]. Following a severe reduction in plasma viremia and a small 
rebound in CD4+ T-cell populations, patients progress to the clinically asymptomatic stage.  
The period of time between the initial primary infection stage and the development of 
AIDS is classified as the clinically asymptomatic stage. After the initial viremia peak and 
subsequent decrease in HIV-1 plasma characteristic of the primary infection stage, HIV-1 continues 
to replicate within infected cells and is readily detected in almost all lymphoid tissue [32, 33]. 
Consistent viral replication results in chronic immune stimulation; this strain on the immune system 




lymphoid tissue [34]. Despite continual propagation of the virus and gradually decreasing CD4+  
T-cell populations, infected patients generally don’t exhibit any clinical symptoms at this stage, as 
immunodeficiency has not progressed enough to compromise cell-mediated immune function.  
The final phase includes both the stage of symptomatic HIV-1 infection as well as the 
progression of HIV-1 to AIDS. While the immunological hallmark of the progression from the 
asymptomatic stage was gradual loss of CD4+ T-cells, the symptomatic stage is defined by a 
steeper decline in CD4+ T cell populations and overall increase in systemic viral load [35]. This is 
due to systemic viral replication at multiple sites in addition to the high amount of replication 
happening within lymphoid tissue. The amount of time required for the development of clinical 
immunodeficiency from the asymptomatic stage is variable among infected individuals: indeed, the 
complexity of host and viral factor interactions are integral to the eventually outcome of the disease 
[28]. Overall, low amounts of viral replication and retention of immune function favors a slow 
progression of HIV-1 infection, while high viremia and immune dysfunction leads to a more rapid 
disease progression. 
1.5 Antiretroviral therapy (ART)   
 The natural history of HIV-1 infection that is outlined in the previous section is dependent 
on infected individuals not being administered any HIV-1 specific treatment during their infection. 
This is representative of the clinical landscape in the decade following the discovery of HIV-1 in 
1983, in which medical professionals were largely ignorant about the virus and its pathology. 
Treatment options were limited if not non-existent during this period; testing positive for HIV-1 
was universally fatal, with survival time directly dependent on the individual’s own progression 
from initial infection to AIDS.    
 This changed in 1987 with the development and testing of a dideoxynucleoside reverse 




treat HIV-1 [6]. Benefits of AZT treatment were limited; greater survival times were found in 
patients at 24 weeks, but this effect was short-lived and by 48 weeks’ time, survival benefits were 
no longer observed [36, 37]. Additionally, AZT treatment showed side effects of transient anemia 
and malaise due to off target toxicities, particularly in high doses given to HIV-1 patients shortly 
after approval. Regardless of AZT’s limitations, the effects seen on the survivability of HIV-1 
patients spurred medical research to investigate the potential of antiretroviral therapy. Three 
additional NRTIs were then released in quick succession: zalcitabine (ddC), didanosine (ddI), and 
stavudine (d4T).   All three medications had particular toxicities and as of present none are widely 
administered within the clinic [38, 39]. However, the development and administration of these early 
antiretroviral drugs, and their associated toxicities, inevitably led physicians to give treatment 
sequentially or to alternate between different therapies, a strategy that would serendipitously prove 
effective as more antiretrovirals became developed [40]. Patients continued to fare poorly within 
the clinic, but with small reductions in the rate of adverse reactions there was optimism 
antiretroviral research was heading in the right direction.  
 Combination NRTI therapy, in which two or more antiretrovirals are given as a treatment 
concurrently, was another clinical concept that showed encouraging results in the early 1990s. The 
development of lamivudine (3TC), a cytidine analog, allowed for another drug to be used in 
combination with other NRTIs and proved to be synergistic with the other compounds [41]. But 
despite such progressions, the quality of life for HIV-1 patients continued to be poor. Triple drug 
combination strategies were the only cases showing any sign of significantly controlling HIV-1 
infection, and early NRTIs, particularly thymidine analogs, continued to have issues with toxicity 
[39].  
 The development of different classes of ARVs was perhaps the most substantial 
advancement of HIV-1 therapeutics. Groups of drugs that have a direct effect on HIV-1 viremia 




at limiting viral resistance while decreasing viral plasma levels. Saquinavir became the first 
protease inhibitor (PI) approved in 1995, but initial formulations struggled with poor bioavailability 
and deactivation by enzymatic metabolization [39]. Ritonavir, another PI, was developed shortly 
after saquinavir. Ritonavir was found to be a potent inhibitor of one of the enzymes responsible for 
deactivating saquinavir, and when given in combination, dual saquinavir and ritonavir 
administration was found to be quite effective at HIV-1 suppression, though tolerability was low 
[42]. Eventually is was determined that high-dose saquinavir and low-dose ritonavir  in 
combination was optimal for effective protease inhibition, and still represents the recommended 
usage for protease inhibition in the clinic at present [39].  Nevirapine became the first non-
nucleoside reverse transcriptase inhibitor (NNRTI) approved in 1996, and it was found that if given 
as a monotherapy that resistance develops relatively quickly. But with nevirapine given as part of 
three-drug regimen, in which two NRTIs are also administered, HIV-1 was found to be nearly 
completely suppressed and proved superior to dual therapy NRTI control groups in the Italy, 
Netherlands, Canada, Australia Study (INCA Study) [43].  
 Different classes of ARV medications, which in turn could be given to patients in a variety 
of different combinations, ultimately proved the key in defeating HIV-1 conferred drug resistance. 
Such drug regimens become referred to as “highly active antiretroviral therapy” (HAART) and 
truly marked a turning point in the battle against the HIV-1 pandemic. A substantial decrease in 
HIV-1 associated morbidity and mortality associated with HAART administration changed the 
world: the leading cause of death among young people within developed countries had become 
augmented to a chronic but manageable affliction [44].  Perpetual variety in HAART treatment not 
only prevents HIV-1 for developing resistance to specific ARVs but also prevents HIV-1 
replication to the point where plasma viral levels are undetectable [45]. To date, there are five 
different classes of antiretroviral medications: NRTIs, NNRTIs, PIs, entry/fusion inhibitors, and 




• NRTIs work to inhibit the enzyme responsible for the transcription of the viral 
RNA into DNA for integration. This is accomplished by NRTIs being nucleoside 
analogs; they compete with natural deoxynucleotides within the cell for 
incorporation into the growing DNA strand during reverse transcription. Such 
analogs lack the 3’ OH group needed to successful chain elongation. When the 
next deoxynucleotide is incorporated into the growing DNA chain, the 5’ to 3’ 
phosphodiester bond needed for continuation cannot be formed.  Failure to form 
this bond halts the process, effectively preventing viral RNA from being reverse 
transcribed. Currently approved NRTIs used in treatment of HIV-1 include: 
Zidovudine, Didanosine, Zalcitabine, Stavudine, Lamivudine, Abacavir, and 
Tenofovir. It should be noted that Tenofovir is a unique type of NRTIs and is more 
accurately described as a nucleotide reverse transcriptase inhibitor (NtRTIs). 
Nucleoside analogs normally undergo phosphorylation to be converted into 
nucleotides, which become active for incorporation. Tenofovir is administered as 
an already chemically active nucleotide analog, with no need for activation via 
phosphorylation  
•  Non-nucleoside reverse transcriptase inhibitors (NNRTIs) again inhibit the 
transcription of viral RNA into DNA but do so by more direct means. NNRTIs 
non-competitively bind to an allosteric site on reverse transcriptase, resulting in a 
confirmation change and inactivation of the enzyme. If given as a monotherapy, 
HIV-1 resistance to NNRTIs can be established fairly quickly due to mutations in 
reverse transcriptase during continual iterations of replication; mutations in which 
NNRTIs cannot bind to the RT allosteric site are positively selected for (REF). 
Because of this, NNRTIs are commonly given in conjunction with one or two other 
NRTIs. Currently approved NNRTIs include: Nevirapine, Delavirdine, Efavirenz, 




• PIs effectively prevent the maturation and release of newly synthesized viral 
proteins by inhibiting the enzyme needed for their cleavage and subsequent 
activation. As described above, once viral RNA has been reverse transcribed into 
DNA and integrated into the host genome, viral proteins are transcribed by host 
cell machinery to produce new viral particles. Newly synthesized viral proteins 
must become cleaved by the viral protease to become fully activated and 
infectious. PIs bind to the active site of viral proteases, preventing them from 
having enzymatic activity and inhibiting the completion of HIV-1 life cycle. 
Currently approved PIs include: Saquinavir, Ritonavir, Nelfinavir, Amprenavir, 
Lopinavir, Atazanavir, Fosamprenavir, Tipranavir, and Darunavir. 
•  Entry and fusion inhibitors are a relatively new class of ARV drugs with only 2 
compounds currently being approved for HIV-1 treatment: Enfuvirtide, approved 
in 2003, and Maraviroc, approved in 2007. For entrance of HIV-1 into a host cell, 
viral envelope surface glycoproteins must interact with membrane surface 
receptors. HIV-1 envelope glycoproteins are normally a heterotrimer consisting of 
three molecules of gp120 and three molecules of gp41. Binding of viral gp120 to 
the CD4 receptor of a host cell causes a conformational change in the glycoprotein, 
allowing interaction with host cell co-receptors CCR5 or CXCR4. Co-receptor 
binding ultimately allows fusion between the host cell membrane and portions of 
gp41 within viral envelope. Enfuvirtide prevents this fusion event by changing the 
N-terminal heptad repeat of gp41 to an inactive hetero six helix bundle, preventing 
it’s fusion interaction with the host cell membrane. Maraviroc utilizes an 
interaction with co-receptor CCR5, binding to it and preventing association with 
gp41, effectively inhibiting entry into cells with the CCR5 co-receptor. 
• Integrase inhibitors were developed to block the enzyme responsible for the 




catalyzes two reactions within the HIV-1 replication life cycle. The first is 3’ end 
processing in which two nucleotides are removed from one or both of the 3’ ends 
of the viral DNA, while the second is the “stand transfer reaction” in which the 
processed 3’ ends are covalently bound to host chromosomal DNA. Inhibition of 
integrase prevents these steps from occurring, effectively preventing the infection 
of the host cell. Currently approved integrase inhibitors are: Raltegravir, 
Dolutegravir, Elvitegravir, and Bictegravir. 
Despite such significant advancements in the development of HIV-1 treatment options, 
HIV-1 persists and remains yet to be completely eradicated. Thought HAART can reduce plasma 
viral levels to undetectable levels and allow patients to live decades after their initial infection and 
diagnosis, HIV-1 continues to persist throughout the world. 
1.6 HIV-1 reservoirs 
HIV-1-infected individuals receiving clinically effective ART must remain on such therapy 
continuously and uninterrupted for the entirety of their lives, despite the effectiveness of such drug 
regimens as described above. This can primarily be attributed to the ability of HIV-1 to escape 
immune surveillance and persist within latently infected immune cells in cellular and anatomical 
locations termed “HIV-1 reservoirs” [46]. Such reservoirs were discovered in the mid 1990’s 
during the development of HAART, in which reports exhibited HIV-1 provirus residing within 
latently infected resting life-long memory CD4+ T lymphocytes [47]. Such cells have HIV-1 DNA 
integrated within their genome but are not actively producing new virions; rather they are in a latent 
resting state until they become activated weeks, months, or sometimes years after they initially 
become infected. Such latency renders the majority of current ARV therapy ineffective; inhibiting 
steps of viral replication has little consequence on cells that are not actively producing new virions. 
Indeed, HIV-1 patients who interrupt continuous ART display rapid viral plasma rebound even if 




infected immune cells often reside in anatomical locations that ARV therapy poorly penetrates, 
allowing for potentially high levels of replication within HIV-1 reservoirs [49]. Such latently 
infected and long lasting groups of immune cells can be categorized based on a commonality 
between the types cells they reside in, or the anatomical location large amounts of such cells accrue.  
Different mechanisms have been proposed for the persistence and maintenance of HIV-1 
cellular reservoirs. These include inadequate penetration of ARV drugs into tissues sites of active 
replication, replenishment of infected cells via residual viral replication, intrinsic stability of 
latently infected and resting CD4+ T-cells, and periodic homeostatic proliferation of cells in 
sanctuary sites located within various tissues compartments [50-53]. Overall, HIV-1 persists 
primarily within immune cells of two broad categories: CD4+ T-lymphocytes of a variety of 
functions including central memory, effector memory, transitional memory, and naïve CD4+ T-
cells, as well as monocyte-derived macrophages. Anatomical locations of HIV-1 sanctuaries are 
also numerous and diverse, with HIV-1 persistence and replication being found in peripheral blood, 
peripheral lymphoid tissue, gut-associated lymphoid tissue, the reticuloendothelial system (RES), 
and the central nervous system (CNS).  
1.6.1 Peripheral lymphoid tissue  
Lymph nodes are a primary site for viral replication of HIV-1, with large amounts of 
infected cells and free virions being contained within the follicular dendritic cell network [29, 52]. 
HAART is effective in reducing HIV-1 RNA levels within lymph nodes, with a clearance half-life 
only marginally longer than that found in blood [54, 55]. However, both HIV-1 RNA and DNA 
can be detected within lymph nodes following years of viral suppression due to various 
combinational ART [56]. A multitude of different studies involving ART-treated SIV-infected 
rhesus macaques found that HIV-1 RNA and/or DNA levels are highest within the lymph nodes 




an association between high levels of viremia and low ARV concentrations within such peripheral 
lymphoid tissues [57-59].  
1.6.2 Gastrointestinal tract and GALT 
Following transmission of HIV-1, the gastrointestinal tract is one of the earliest targets of 
HIV-1 infection and is one of the tissues with the highest number of infected cells. This is primarily 
due to the gut containing a large portion of the lymphoid tissue and lymphocytes within the body 
[60, 61]. In vitro studies of isolated primary gut mucosal CD4+ T-cells not only show an increased 
susceptibility to HIV-1 infection but also support increased levels of viral replication [62, 63]. Such 
findings are attributed to these cells having increased T-cell activation and greater levels of CCR5 
expression [64]. Clinical investigations of HIV-1 RNA and DNA levels within rectal biopsies 
showed the viremia remained stable over 1 year of ART, with gut HIV-1 DNA+ cells being twice 
that in blood [65]. Additional studies report HIV-1 DNA levels per million CD4+ T-cells were 5-
6 times higher within the ileum compared with blood in patients that had been taking ART for up 
to 10 years [66]. Averaging the level of HIV-1 DNA across 4 separate gut sites, it was estimated 
that the gut harbors 83-95% of all HIV-1 infected cells within the body [67]. Again, such 
phenomena can be attributed both to the gut intrinsically having large amount of lymphocytes as 
well as poor penetration of certain ARVs into the gut.  
1.6.3 Reticuloendothelial system  
The reticuloendothelial system is also referred to as the mononuclear phagocyte system 
and consists primarily of monocyte and macrophage cells. While the RES encompasses multiple 
different immune cells within different tissue sites, for the purpose of this dissertation focus will 
be put on monocytes of bone marrow and peripheral blood, residual macrophages of the spleen, 
and Kupffer cells of the liver, as these are the areas of biological interest that are targeted in chapter 




and, once associated with a particular tissue, no longer replicate [68]. The utility of MPs is primarily 
that of phagocytosis, in which cells engulf cellular debris and/pathogens and become antigen 
presenting cells (APC). While the percentage of MP cells that become infected with HIV-1 is quite 
low in comparison with that of CD4+ cells, the biological consequences of such infection are drastic 
[69]. Additional utility of MPs consist of the ability to infiltrate a large variety of different tissue 
sites: such cells containing HIV-1 would have a “trojan-horse effect” as they would carry HIV-1 
into anatomical sites that free virions or even infected CD4+ T-cells would not be able to access, 
particularly the brain as discussed below. Therefore, infected MPs are significant contributors in 
the establishment of HIV-1 reservoirs.  However, the migratory behavior of MPs, coupled with 
their large intracellular compartments, make them ideal targets in the establishment of drug depots, 
as discussed in later chapters. Multiple studies have confirmed that presence of infected Kupffer 
cells within the liver as well as the presence of infected red pulp macrophages within the spleen, 
with one study finding evidence of compartmentalization between the plasma and the spleen [70, 
71].  
1.7 Central nervous system as a major reservoir1  
Of all the complications of HIV-1, the most foreboding and chronic issue is the disease’s 
effects on the nervous system. Soon after the discovery and description of AIDS, neurological 
impairments were described and associated with advanced disease and profound immune 
suppression [72, 73]. These aggravations can often become severe with a triad of cognitive, motor, 
and behavioral disturbances [74-79]. Whether directly caused by the virus or indirectly misfolded 
and aggregated proteins, all of the processes discussed underlie the tempo and progression of 
disease [80-86]. A significant body of data has emerged in the past twenty five years on how HIV-
1 affects the brain and causes progressive clinical impairment [72-74, 87-89]. Particular focus will 
                                                          
1 This material was originally published in Comprehensive Textbook of AIDS Psychiatry: A Paradigm for 





be given here on how HIV-1 can pass the blood brain barrier (BBB) into the brain and the cellular 
targets of HIV-1 after entering the brain parenchyma. 
1.7.1 Entry into the brain  
HIV-1 is thought to gain entry to the protected environment of the CNS via a variety of 
different routes, and it is likely that HIV-1 invasion into the brain is achieved by utilizing more 
than one path [90-92]. Several mechanisms have been proposed by which HIV-1 gains entry into 
the brain [93]. In the most prominent and well supported theory, HIV-1 enters the brain inside 
infected macrophages, migrating into the brain parenchyma through BBB disruption and 
establishment of a chemokine gradient. This model is commonly referred to as the “Trojan horse 
hypothesis,” as HIV-1 buds into intracytoplasmic vesicles in macrophages with limited expression 
of viral proteins on the cell surface, allowing for escape from immune surveillance [94, 95]. An 
alternative theory is that cell-free HIV-1 virus directly infects the endothelial cells and astrocytes 
of the BBB, however, this model is partially flawed as there is low or nonproductive infection of 
cells of the BBB [96]. In another model, the transcytosis model, HIV-1 invades the CNS through 
internalization of the virion by endothelial cells or by astrocyte foot processes by macropinocytosis 
or endosomes, with subsequent transfer of the virus to CNS cells [97].  In the brain, monocyte-
derived perivascular macrophages are the main cell type infected by HIV-1, with limited expression 
in microglia and restrictive/non-productive replication within astrocytes [20, 98, 99]. The virus 
replicates within the infected macrophages and can infect other CNS cells, particularly other 
macrophages that perpetuate the infection within the CNS. Astrocytes and capillary endothelial 
cells have been found to contain HIV-1 protein and DNA in infected individuals [20]. Depending 
on the number of infected brain macrophages, the extent of CNS inflammation, and the number of 
recruited monocyte-derived macrophages, the course and extent of neurological impairment can be 
tentatively predicted. 




immune activation of the brain parenchyma, resulting in a subsequent increase in the number of 
microglial cells, up-regulation of MHC class II expression, and local production of cytokines. In 
the normal CNS, neurons, oligodendrocytes, astrocytes, and microlgia are intimately associated 
with each other and communicate through specialized synapses and cell junctions; this direct cell 
contact is required for proper glia maturation and function [100-102]. For glia to undergo 
transformation to an activated amoeboid phenotype, they need to be freed from inhibitory neural 
and astrocytic responses [25]. Activated microglia and, to a lesser extent, astrocytes express MHC 
class I and II antigens and adhesion molecules and secrete cytokines and reactive oxygen 
intermediates, and all have been shown to be important factors contributing to HAD [25, 103, 104]. 
Microglia and astrocytes produce chemokines and control monocyte migration across the BBB 
[105-109]. The event(s) triggering monocyte invasion into the nervous system likely involves the 
secretion of macrophage attractant chemokines and the up-regulation of adhesion molecules on 
activated endothelial and immune cells. Proinflammatory factors induce cytokines and chemokines 
(such as IL-8, IFN-γ, IP-10, growth-related oncogene α [GRO-α], MIP-1a, MIP-1b, RANTES, and 
MCP-1) found in infected brain tissue and may also participate directly in the disease process. Both 
cytokines and HIV-1 Tat induce expression of E-selectin on BMVEC. The likelihood of this event 
is increased by the release of nitric oxide (NO). TNF-α and Il-1β also induce expression of VCAM-
1 on the BMVEC [110]. This induction of adhesion molecules allows binding of HIV-1-infected 
cells to the brain endothelium. Virus and activated macrophage entry into the brain is likely 
precipitated by BBB damage heralded by activation of brain MP. Neuronal damage and alterations 
in the integrity of tight junction and/or regulation of its immune function occur as consequences of 
viral and cellular secretory products and are crucial to HIV-1 brain transport [109]. 
The BBB consists of a monolayer of specialized, non-fenestrated, microvascular 
endothelial cells. Associated with the BBB is a capillary basement membrane on the abluminal side 




These together serve to restrict movement of cells and macromolecules, including viral particles, 
throughout much of HIV-1 infection. Nonetheless, a number of biological situations enable the 
aberrant trafficking of cells across the BBB as a result of HIV-1 infection, allowing for the virus to 
enter the brain. The movement of viral particles from the periphery into the brain is facilitated 
through immune and structural BBB compromise. This process occurs late in the course of disease 
and serves to speed the overall pathogenic process of the disease. HIV-1 infection alters the BBB 
itself; numerous functional and structural abnormalities are of consequence, including damage to 
the basement membrane, damage to tight junction proteins, morphological and functional 
alterations of the BMVEC, and subsequent protein leakage [112-117]. As a result, HIV-1-infected 
monocytes and/or CD4+ T lymphocytes as well as cell-free virus are able to cross the BBB [114, 
118]. 
Inflammation also serves to enhance trafficking of cells across the BBB. ICAM-1, VCAM-
1, and E-selectin are up-regulated on the surface of BMVEC and astrocytes after exposure to 
proinflammatory factors secreted from microglia and astrocytes and/or activated leukocytes from 
the periphery; these serve to augment the process of adhesion molecule expression on not only 
BMVEC but astrocytes as well [106, 119]. Late in the disease process, inflammatory cytokines are 
produced at high levels and allow the BBB to be more easily breached. These proinflammatory 
cytokines induce a transient increase in endothelial permeability by increasing secretion of 
endothelial vasoactive factors, such as NO [120]. TNF-α and IL-1β increase the production of other 
inflammatory mediators, including arachidonic acid–derived PAF [106, 107, 121]. These serve to 
promote monocyte migration across the BBB and ultimately into the brain parenchyma. The 
adhesion molecules ICAM-1 and VCAM-1 on the luminal surface of the BMVEC bind LFA-1 and 
Vl-4 on the monocyte, resulting in migration of the monocyte between the endothelial cells during 
the early stages of viral infection.  




influence transmigration of inflammatory cells into the CNS. Chemokines are secreted at sites of 
inflammation in all tissues and work to guide leukocytes in a concentration-dependent manner[122-
124]. Importantly, specific chemokines will attract specific populations of leukocytes. MIP-1α and 
MCP-1 levels are increased during HIV-1 encephalitis and are potent chemoattractants for 
macrophages as well as CD4+ T lymphocytes [121, 125]. Increasing damage to the BBB impairs 
its ability to protect the CNS from the periphery resulting in cells and toxins being able to reach the 
CNS unchecked. Levels of inflammatory factors greatly increase and lead to a cascade of events 
culminating in further BBB dysfunction. These processes, taken together, affect MP-induced 
neuronal destruction during HAD. 
The Trojan horse hypothesis is based on the concept that infected monocytes and 
lymphocytes act as cellular vehicles that can transport HIV-1 across the BBB, crossing from the 
periphery to the CNS. The specific mechanism of this process has not been completely elucidated, 
however, observations as well as a substantial body of scientific data support this claim. Monocytes 
and CD4+ lymphocytes the primary target of HIV-1 infection outside of the CNS, and analysis of 
HIV-1 infected brains have found large accumulations of HIV-1 infected macrophages within 
neuronal tissue [126-128]. Expression of adhesion molecules as well as chemo attractants within 
the CNS is higher in individuals experiencing HIV-1 dementia, allowing increased interactions 
between infected leukocytes and brain endothelium plus increased recruitment of these monocytes 
for transmigration [129].  
These observations converge into the idea of a “snowball” like effect, in which initial HIV-
1 invasion occurs in very small amounts, with increasing levels of invasion facilitated by signaling 
initiated by the resulting microenvironment of the initial migrating infected cells. Indeed, several 
groups have reported findings supporting this claim. HIV-1 infection of human peripheral blood 
monocytes resulted in higher expression levels of LFA-1, and factors released by these infected 




130]. Upon immunohistochemical analysis of HIV-1 infected brain tissue, E-selectin levels were 
substantially increased in HIV-1-demented individuals as compared to non-demented patient’s 
brain samples [115, 117].  
Chemokines play a vital role in the transmigration process, and studies have reported 
aberrant expression levels of both chemokines and their respective cell surface receptors in HIV-1 
infected leukocytes [101, 123]. Monocyte chemotactic protein 1, or MCP-1 (also referred to ass 
CCL2) has long been established as a principal attractant for monocytes and activated t-cells, and 
studies have indicated that it is integral for monocyte transmigration into the brain parenchyma 
[131]. Analysis of CSF from HIV-1 infected patients exhibiting dementia found elevated levels of 
MCP-1 [132, 133]. These findings, taken together, indicate that adhesion molecules and 
chemokines likely play an important role in facilitating leukocyte transmigration and subsequent 
invasion of HIV-1 into the CNS.  
Although the major targets of HIV-1 in the brain are macrophages and microglia, there 
have been some reports of other cells of the brain being infected by HIV-1, including the endothelial 
cells of the BBB [134, 135]. This highlights another theory of HIV-1 entry into the CNS; direct 
infection of perivascular endothelial cells and astrocytes within the blood brain barrier.  The support 
for this hypothesis is weak, and suggests that this route of viral entry occurs only in small amounts, 
most likely in conjunction with the other entry mechanisms discussed. Groups have reported that 
in HIV-1 infected patients, brain microvascular endothelial cells (BMVECs) have exhibited 
dysfunction and rampant apoptosis [136, 137]. Astrocyte viral infection is very low and often 
results in minimal reproduction of the virus, however, several studies have demonstrated that 
astrocytes that do become infected increase toxicity and inflammation surrounding CNS cells, thus 
propagating HAND pathology [129]. It is also possible that infection of astrocytes occurs only the 
late stages of the disease, long after the initial invasion of the virus, as one study concluded that up 




correlation between areas of HIV-1 infected astrocytes and increased rate of macrophage/monocyte 
transmigration [134]. Based on these findings, it is unlikely that direct infection of endothelial cells 
and astrocytes is the main mode of HIV-1 entry into the CNS. However, it is plausible that these 
cells, once infected, can participate in subsequent infection of other cells in the CNS and lend a 
hand in the creation of a viral reservoir.  
Another possibility of HIV-1 invasion into the CNS is that transcytosis, in which 
endothelial cells or astrocytes absorb the HIV-1 virion via macropinocytosis or endosomes and 
mediate transfer to CNS cells. While the basic idea of this hypothesis is supported with compelling 
data from multiple groups, the precise mechanism has yet to be determined and is entangled in 
controversy within the scientific community [138, 139].  One group has reported the process being 
pH independent and thus non-endosomal, while others have indicated for a pH dependent 
mechanism [114, 140]. In vitro studies using electron microscopy have shown viral particles 
localized within structures comparable with endosomes [114]. Increased surface microvilli of brain 
endothelial cells and increases in numbers of cytoplasmic vesicles are indicative of 
macropinocytosis, with both findings demonstrated experimentally in vitro [141]. While it is 
evident that endothelial cells and astrocytes have the capability to acquire HIV-1 by transcytosis, 
how these cells transfer and propogate infection of the virus to other cells within the CNS has yet 
to be investingated. 
1.7.2 HIV-1 targets within the CNS 
1.7.2.1 Mononuclear phagocytes  
The pathogenesis of HIV-1-associated CNS disease centers around mononuclear 
phagocytes (MPs), which include blood borne macrophages, dendritic cells, tissue macrophages, 
and microglia.. Macrophages are the principal cell infected in the brain and become activated and 
recruited into tissue during inflammation and emigrate into the CNS during disease [128, 142]. 




process has subsided. For HIV-1-encephalopathy and HIV-1 associated dementia (HAD), the 
process never subsides, as brain inflammation is continuous and induced by ongoing viral 
replication. Mononuclear macrophages are preferentially infected by HIV-1 due to their CD4 
receptor and CXCR4 co-receptor; both of which help mediate the fusion of the HIV-1 envelope 
with the host cell membrane. Subsequent activation and differentiation into macrophages further 
increases the efficiency in which these cells replicate and spread the virus [126, 143]. Such cells, 
once in the CNS, initiate a “pull” mechanism of activation and recruitment via chemotactic and 
inflammatory signals such that more monocytes are attracted to the brain, increasing the amount of 
HIV-1 as well as activating and infecting other cells within the CNS.  
The perivascular macrophage is an actively studied MP cell type with involvement in HAD 
pathogenesis. Normally these cells exist between the glia limitans and basement membrane of the 
choroid plexus and CNS capillaries and are derived from circulating monocytes. Because of their 
anatomical proximity to cerebral vessels in the brain, perivascular macrophages are likely 
susceptible to HIV-1 that crosses the BBB [144]. .They are in close association with the bone 
microvascular endothelial cells (BMVEC), and this collaboration allows them to serve as sentinels 
for the CNS. In fact, perivascular macrophages act as intermediates between the peripheral 
circulation and the microglia. Since microglia are in contact with these macrophages, signals may 
be rapidly communicated deep into the CNS from interactions at the perivascular space. 
Transmission of virus and/or inflammatory responses in the brain may occur between these 
perivascular macrophages and glial cells [20, 128, 145]. 
Parenchymal microglia occur in significant numbers in the CNS and may constitute up to 
10% of CNS cells. These cells enter the CNS during gestation and have a very low turnover rate 
[100, 128], in contrast to perivascular macrophages, which are continuously replenished from the 
bone marrow. Parenchymal microglia act as the resident macrophages within the brain and are 




and macrophages in the CNS are easily distinguished from each other by morphology, but 
activation of microglia results in them displaying macrophage-like properties [146]. There are two 
morphological subtypes of microglia. The first, ramified microglia, are resting cells with reduced 
secretory and phagocytic activity making up the web of microglia that span the CNS [146, 147]. In 
contrast to perivascular macrophages, they have weak antigen-presenting capability. The second 
morphological subtype, amoeboid in form, is a morphological intermediate and transitional cell 
between the ramified microglia and the brain macrophages [146]. This subtype is not found in the 
normal adult CNS but rather in inflammatory and demyelinating conditions. 
Infection of brain MPs eventually leads to the formation of multinucleated giant cells 
(MGC). These cells result from the fusion of HIV-1-infected brain MP with uninfected monocyte-
derived macrophages (MDM) or microglia [99, 128, 148]. This fusion is mediated by HIV-1-
envelope glycoproteins present at the surface of infected cells with CD4 and chemokine receptors 
at the surface of uninfected cells [15, 149-151]. The MGCs are large, irregularly round, elongated 
or polyhedral, with dense eosinophilic cytoplasm in the center and vacuolated at the periphery 
[148]. MGC formation is found throughout the brain in HIV-1 disease, but is characteristically seen 
primarily in the deep brain structures and most commonly in subcortical white matter. Although 
pathognomonic of HAD, giant cells are only found in 50% of patients [25, 26, 152]. 
1.7.2.2 Astrocytes 
Astrocytes are critical for the survival of neurons and their function may be impaired in the 
context of HIV-1 infection. Astrocytes are responsible for maintaining homeostasis in the CNS and 
are important in the detoxification of excess excitatory amino acids such as extracellular glutamate 
levels [153, 154]. However, infected astrocytes can produce cellular factors that may adversely 
affect neuronal survival [121, 155, 156]. Astrocytes play a dual role in the pathogenesis of HIV-1-
related encephalopathy; in HIV-1 infection, astrocyte glutamate reuptake is impaired, possibly due 




by activated macrophages [157]. Activation of the CXCR4 receptor by stromal cell-derived factor 
1 (SDF-1) results in the release of extracellular TNF-α and downstream release of glutamate [157]. 
During HIV-1 infection there is an amplification or regulation of neurotoxic signals among 
astrocytes and microglia. The HIV-1 protein Tat induces expression in astrocytes of MCP-1, a 
chemoattractant for macrophages, and IL-8 and inducible protein-10 (IP-10), which attract multiple 
leukocyte types [124, 132]. 
Astrocytes both proliferate and undergo apoptosis in HIV-1 CNS infection [154]. The level 
of astrocyte apoptosis correlates strongly with both the severity and rate of progression of HIV-1 
dementia. Direct infection of astrocytes by HIV-1 is minimal due to an absence of the CD4 receptor 
[158]. Although studies have reported that infection of astrocytes can be both productive and 
unproductive, recent studies have concluded that productive HIV-1 infection of astrocytes is 
infinitesimally small, with .0025% of brain astrocytes undergoing productive infection [134, 158]. 
HIV-1 virus enters these astrocytes via endocytosis in which endosome internal machinery 
degrades the majority of the viral particles; thusly HIV-1 astrocytic endocytosis is seen as a “kiss 
of death”, as only a very small amount of viral particles survive and establish a productive infection 
[158].  Unproductive infection of astrocytes occur more frequently, with groups reporting 3-19% 
of astrocytes within infected brain tissue carrying HIV-1 DNA [134, 159].  
1.7.2.3 T-cells 
. CD4+ T cells serve as important reservoirs of HIV-1, as a small proportion of these 
cells harbor HIV-1 in a stable, inactive form. Normal immune processes can activate these 
cells, resulting in the production of new HIV-1 virions. After transmigration through the 
BBB, T cells are able to instigate cell-to-cell spread of HIV-1 through CD4-mediated 
fusion of an infected cell with an uninfected cell. In addition, phagocytosis of CD4+ T cells 




after insult to the CNS and can initiate both protective and toxic inflammatory responses 
[162]. Protective responses are elicited through elimination of the ongoing infectious agent 
by innate, humoral, and cytotoxic immune activities. Nonetheless, widespread 
inflammation in the setting of HIV-1 often leads to damage of the BBB and further 
transendothelial migration of leukocytes entering the nervous system [109]. Inflammation 
of the brain and spinal cord actively attracts T cells to the CNS. Macrophage inflammatory 
protein-1 alpha (MIP-1α) and MIP-1β are relevant to the cellular recruitment and immune 
activation during HIV-1 infection, as both use CCR5 as their receptor [122, 163-166]. MIP-
1α selectively attracts CD8+ and MIP-1β recruits CD4+ lymphocytes. Both MIP-1α and 
MIP-1β are produced by HIV-1-infected monocytes and are closely linked to viral 
replication [125]. 
During HIV-1 infection, more T cells are activated to a blast phase [167-169]. Once within 
the CNS, the lymphoblasts search for antigen as they migrate through the parenchyma. Such cells 
can easily encounter and engage perivascular macrophages through direct cell-to-cell contact or 
through soluble factors released. CD4+ T lymphocytes are responsible for most of the HIV-1 
replication in the periphery, and HIV-1 may enter the CNS in infected lymphocytes during the late 
stage of the disease. As the T cells migrate through the parenchyma, they secrete the cytokines that 
lead to activation of MP and an amplification of inflammatory cell responses throughout the CNS 
region involved [170]. If these activated T cells are infected, they will shed virus as they migrate. 
At the same time, they induce CD4 expression on cells susceptible to HIV-1 infection, rendering 
them even more susceptible. T cells expressing the CD40 ligand (soluble and bound forms) can 
activate both infected and noninfected monocytes that express TNF-α and CD40 receptors [167, 
171, 172]. Macrophages become activated by way of scavenger receptors as they clear the debris 




direct cytopathic effects of HIV-1 may be attributed to cell death [173]. The decline in CD4+ T 
lymphocytes allows macrophages, without control, to express a metabolically active, tissue-
destructive phenotype. 
1.8 ART associated neurotoxicity 
While it is likely that HIV-1 invasion into the brain and a subsequent inflammatory cascade 
is responsible for the development of adverse neuropsychiatric events in infected patients, other 
potential mechanistic causes are certainly possible. Such reasoning is a result of the prevalence of 
HAND remaining consistent in groups of infected individuals despite the introduction of HAART, 
with 15-55% of HIV-1+ individuals estimated to have HAND, a proportion comparable to the pre-
cART era [89, 174]. It should be noted that more recent HAND cases in the era of HAART 
represent more milder forms of the condition, however, additional studies have indicated that 
HAND becomes more prevalent and severe as patients grow older [89, 174]. Additional risk factors 
for the development of HAND include cardiovascular disease, age, co-infection of hepatitis C, 
substance abuse, and concomitant psychiatric illnesses [175]. Therefore, it is likely that the onset 
of neuropsychiatric complications is multifactorial, with many causes working in tandem to 
propagate HAND in HIV-1 infected patients. A potential contributor to HAND pathology not yet 
discussed is that of the antiretroviral medications themselves. Indeed, while the introduction of 
cART has resulted in a marked reduction in morbidity and mortality in HIV-1 infected patients, the 
off target effects can be quite substantial [176, 177]. 
Unfortunately, little information on the effects of antiretrovirals within the CNS is 
available, with studies of off target neurotoxicity in ART cohorts being reported only within the 
past decade [178]. This can partly be attributed to more recent ART development being focused on 
drugs that can pass the BBB to readily control the HIV-1 CNS viral reservoir; increasing ARV 
concentrations in the brain would result in decreased CNS viremia, subsequently leading to a 




previous observations of severe AIDS associated dementia seen in the pre ART era, it would seem 
that decreased ARV brain concentrations causing less neuropsychiatric problems would be the 
opposite expected effect.  However, one such study found exactly that. In a group of 
immunologically and virologically suppressed patients, researchers found that patients reported 
improved cognitive abilities for up to 96 weeks following election to cease treatment [179]. Such 
findings were opposite of the groups expected hypothesis and raised the possibility that low ARV 
concentrations within the brain, while effectively reducing brain viremia, can have some 
detrimental effects.  
The NNRTI Efavirenz has long been considered an excellent antiretroviral particularly 
when used in combination, such as Combivir (lamivudine/zidovudine), Kivexa 
(abacavir/lamivudine), and Truvada (tenofovir/emtricitabine) [180]. While these therapies are 
extremely effective at systemically reducing viral load, the most consistently reported side effect 
of efavirenz is neurotoxicity, with one study reporting 40-60% of patients on efavirenz having CNS 
toxicity, and 25-40% exhibiting psychiatric effects [181]. In multiple studies the number of CNS 
effects attributable efavirenz is almost double that of other antiretrovirals it was compared to [182-
184]. These off-target toxicities within the CNS contribute to a higher numbers of discontinuation 
of therapy compared to newer, less toxic drugs, further compounding problems with HIV ART 
compliance.  
Additional studies investigating ARV neurotoxicity have found that a variety of 
antiretrovirals have exhibited toxic effects on neurons; however, such studies were performed on 
in vitro neuronal cultures and as such conclusions are limited. Highest neurotoxicity within neurons 
was seen in abacavir, efavarenz, etravirine, nevaripine, and atazanavir, with some toxic 
concentrations overlapping drug levels clinically found within the CNS of patients [178]. In 
general, clinically relevant concentrations showed modest levels of toxicity. Nonetheless, such 




required to suppress viral replication and to guide the use of compounds that will minimize CNS 
complications.  
Dolutegravir, a potent integrase strand inhibitor, is one of the more recent ARV drugs to 
come to market with its medical use being approved in 2013. DTG readily crosses the BBB and 
has been found to accumulate within CNS tissues. Additionally, some of the more commonly 
reported side effects of DTG administration is that of headache and insomnia. Though these off 
target effects are minor and generally well tolerated, they still raise concern of DTGs contribution 
to adverse neuropsychiatric events in HIV-1 patients. Furthermore, a recent study following DTG 
administration to women at the time of conception exhibited a potential increased risk for neural 
tube defects in their newborns [185].  
1.9 Theranostics  
 Over recent decades, nanotechnology has garnered a considerable amount of interest 
within the scientific community, with medical research being no exception. Indeed, the ability to 
reliably and consistently produce materials with dimensions and tolerances of less than 100 
nanometers (nm) has proven extremely useful across a diverse multitude of research fields. The 
impact nanotechnology has had on medicine, both in research laboratories and within the clinical 
landscape, cannot be understated.  Constant innovation in the synthesis and characterization of 
nanoscale materials has resulted in products with high amounts of utility.  
However, until recently, nanotechnology developed for medical purposes has largely been 
one-dimensional. Development and production of nanomaterials were done for the utilization of a 
single function; to diagnose and/or provide information on a disease state, or to provide therapy for 
the treatment of a disease state [186]. These nanoscale diagnostic agents and nanomedicines have 
proven to be independently useful, with particular success being found in sequential utilization of 
their single functions. To first make a diagnosis and acquire details on the progression of a disease, 




disease based on previously acquired diagnostic information, has proven useful in patient 
management. But these independent functions, diagnosis and therapy, have required independent 
nanomaterials. Such a two-part strategy has proven ineffectual for disease states with diverse 
presentations within the clinic and complicated underlying pathology. Furthermore, the most 
significant diseases impacting humanity today have complex disease progressions. 
The term “theranostics” was coined from the concept of combining both therapeutic and 
diagnostic nanomaterials into a single platform [187]. Such combination would allow both 
nanomaterials to be delivered together, allowing for concurrent treatment and monitoring of a 
disease state. Theranostics is a cornerstone strategy for personalized medicines, allowing for 
identification of subgroups of patients with specific clinical profiles that are most likely to respond 
to specific therapies, while also identifying within those same subgroups patients that would have 
adverse reactions to these same therapies [186].  
We developed theranostic nanoparticles for real-time tracking of therapy biodistribution in 
the treatment of HIV-1. Termed “multi-modal imaging theranostic nanoprobes”, such 
nanotechnology allowed combined bioimaging, drug pharmacokinetics, and tissue biodistribution 
tests in animal models [188]. Individual components include a diagnostic paramagnetic contrast 
agent in cobalt ferrite, a diagnostic fluorescent component in incorporated Europium (Eu3+), and 
HIV-1 therapy in nanoformulated dolutegravir (DTG). Brief descriptions of each of these  
components are described below.  
1.9.1 Paramagnetic and superparamagnetic contrast agents  
  Magnetic resonance imaging (MRI) has proven to be a powerful and non-invasive 
diagnostic modality since it’s development in the 1970’s [189]. MRI utilizes strong magnetic fields, 
magnetic field gradients, and radio waves for interaction with the protons within a living organism, 
allowing for generation of internal images. Specifically, MRI generates contrast based on intrinsic 




times, and proton density. In some disease states, it is possible to differentiate diseased tissue from 
healthy tissue based on disease’s effect on these intrinsic differences. However, often times the 
effect of disease pathology on these factors is too limited for any meaningful diagnostic information 
to be discerned from the resulting images. Because of this, multiple “contrast agents” have been 
developed that can drastically change the intrinsic relaxation times of specific tissues.  
 “Paramagnetic” materials can be defined as those that are weakly attracted by an external 
magnetic field and form internal, induced magnetic fields in the direction of a specific applied 
magnetic field [190, 191]. Paramagnetic contrast agents include manganese (Mn2+) and gadolinium 
(Gd) that substantially shorten T1 relaxation of water protons, creating a brightened contrast in T1 
weighted MR images. Superparamagnetic contrast agents such iron oxide particles or cobalt ferrite 
nanoparticles shorten T2 relaxation times of water protons, creating a “darkening” effect on T2 
weighted MR images [192]. Additionally, superparamagnetic contrast agents show much more 
magnetic susceptibility compared that paramagnetic contrast agents, leading to an increase in 
magnetic sensitivity.  
1.9.2 Fluorescence  
Fluorescence can be defined as a substance emitting light of a specific wavelength after 
said substance has absorbed light or other electromagnetic radiation. Utilization of such a property 
has proven useful in biological sciences, as application of fluorescent materials to a vehicle allows 
for non-destructive tracking or analysis through different biological pathways. This can be 
performed at specific emission frequencies in which there is no background from excitation light, 
as very few biological components are naturally fluorescent. Such “fluorescent labeling” can be 
done via a very large variety of different fluorophores such as dyes and fluorescent proteins, each 
with a unique excitation and emission wavelength, molecular weight, and quantum yield [193].  
Additionally, specific elements exhibit intrinsic fluorescence. Rare-earth doped phosphors such as 




Incorporation of rare earth element Eu3+ into our nanoparticle vehicle proved particularly useful, 
exhibiting fluorescence and emission wavelengths at 410 nm and 660 nm, respectively. Europium 
doping within the spinel ferrite structure of our theranostic nanoparticles allowed for subcellular 
tracking using both in vitro and ex vivo confocal microscopy, as described in both chapter 2 and 
chapter 3 
1.9.3 Nanoformulated ARVs 
 The final component of our theranostic nanoparticles was that of nanoformulated ARV 
drug, specifically the integrase inhibitor dolutegravir. Considerable innovation has occurred in the 
production of long-acting ART regimens in efforts to reduce secondary toxicities, improved drug 
adherence, and prevent new infections [195]. Ultimately, such goals center on drastically increasing 
the half-life of ARV drugs by improving upon their hydrophobicity. Formation of cell and tissue 
penetrate nanocrystals that are protected by biodegradable polymers allow the establishment of 
drug depots within monocyte-macrophages, prolonging drug half-life. [195, 196] However, a major 
drawback of developing long-acting ARV formulations is that biodistribution and pharmacokinetic 
studies, often taking weeks to months, are tedious and burdensome. Incorporation of long acting 
ARV drug into theranostic nanoparticles, in conjunction with other components, allows a much 
more rapid screening of tissue biodistribution and pharmacokinetics, subsequently resulting in 
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2.1 Introduction  
A major unmet need in the treatment of HIV-1 infection rests in long-term adherence to 
antiretroviral therapy (ART). If brought into clinical practice, long-acting ART regimens would 
substantively improve drug adherence, reduce secondary toxicities and prevent new infections. 
These could ultimately facilitate the realization of an AIDS-free world [195, 197-201]. In efforts 
to complete this task, we improved the hydrophobicity of existing antiretroviral drugs (ARVs), 
leading to the formation of cell- and tissue-penetrant nanocrystals protected inside biodegradable 
polymers. These were made to establish drug depots within monocyte-macrophages [202-207]. A 
critical component for formulation development rests, in measure, on nanoparticle decoration with 
macrophage-targeting moieties in order to best facilitate drug reservoir targeting. Such advances, 
if realized, will speed the development of eradication measures or, at the least, make therapeutics 
more accessible to larger patient populations. However, a significant obstacle remains in the ability 
to rapidly screen drug formulation tissue biodistribution and pharmacokinetics (PKs) in order to 
realize substantive pharmacodynamic (PD) improvements. This is of particular importance as, 
while the half-lives of each of the few existing long-acting drugs measure in weeks or even months, 
drug tissue distribution is limited [200, 208-212]. To overcome these technical and biologic 
challenges, multimodal decorated nanoparticles were produced where hydrophobic ARVs and 
bioimaging agents were encased in a single nanoformulation. All were placed into one “multimodal 
imaging theranostic nanoparticle” using core-shell construction methods [213]. The surface of the 
particle was coated with lipids decorated with targeting moieties, while the drug and image contrast 
agents were incorporated into a polymeric core. The formed particles were rapidly taken up by 




hydrophobic drug dolutegravir (DTG) were packaged in a polycaprolactone (PCL) core. A lipid 
layer coated the particle’s “shell”. L-α-phosphatidylcholine (PC), 1,2-distearoyl-
phosphatidylethanolamine-methyl-polyethyleneglycol conjugate-2000 (DSPE-PEG2000) and 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) lipids enhanced particle biocompatibility and 
lipophilicity, facilitating macrophage targeting [214]. Macrophage receptors sped entry of the 
ligand-coated drug particles. The folic acid (FA) receptor on macrophages enhanced particle cell 
entry [215-220]. Nanoparticles were produced with consistent size and stability, reflected in long-
acting slow effective drug release (LASER) ART profiles [202, 206]. This enabled depot formation 
for viral reservoir targeting [206]. Overall, the newly generated theranostic nanoparticles provided 
a platform for effective nanoformulated ARV development. 
2.2 Materials and methods  
2.2.1 Reagents  
Iron(III) acetylacetonate (Fe(acac)3), cobalt(II) acetylacetonate (Co(acac)2), europium(III) 
nitrate hydrate (Eu(NO3)3·5H2O), folic acid (FA), oleic acid, oleylamine, lipopolysaccharide 
(LPS), poly(vinyl alcohol) (MW 30,000-70,000, 87-90% hydrolyzed), L-α-phosphatidylcholine 
(PC) (from egg yolk), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 
dicyclohexyl-carbodiimide, N-hydroxysuccinimide, low gelling temperature agarose, coumarin-6, 
iron and cobalt standards for ICP-MS (TraceCERT®) and nitric acid (TraceSELECT®) were 
obtained from Sigma-Aldrich, St. Louis, MO, USA. Polycaprolactone (PCL) (MW 43,000-50,000) 
was obtained from Polysciences, Inc. Warrington, PA, USA. 1,2-Distearoyl-
phosphatidylethanolaminemethyl-polyethyleneglycol conjugate-2000 (DSPEPEG2000) and 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) were obtained from Corden Pharma 
International, Plankstadt, Germany. DTG was obtained from BOC Sciences, Shirley, NY, USA. 
1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N- [amino(polyethyleneglycol)-2000] (DSPE-




2.2.2 Synthesis of DSPE-PEG2000-FA Conjugates 
FA-modified DSPE-PEG2000 was synthesized by a multi-step process. FA was activated 
by conversion to a N-hydroxysuccinimide ester (NHS-FA) [221]. FA (237 mg; 0.536 mmol, 1 
equiv.) was dissolved in 10 mL of anhydrous dimethyl sulfoxide (DMSO, 10 mL) and triethylamine 
(80 µL, 0.569 mmol, 1.1 equiv.) and allowed to stir at room temperature for 18 h under argon and 
protection from light [222]. Dicyclohexylcarbodiimide (111 mg; 0.533 mmol, 1 equiv.) and N-
hydroxysuccinimide (123 mg; 1.0 mmol, 2 equiv.) were added to the FA solution then stirred for 
an additional 16 h. The resulting NHS-FA solution was separated from insoluble dicylohexylurea 
by filtration then reacted with DSPE-PEG2000-NH2 (500 mg; 0.179 mmol, 0.3 equiv.). The 
mixture was stirred for 3 days at room temperature under argon and light protection. The DSPE-
PEG2000-FA conjugate was precipitated from ether (~150 mL) and collected by centrifugation at 
215 × g for 15 min. The pellet was dried under vacuum, dissolved in methanol (~25 mL) and 
purified on a sephadex LH-20 column using a coumarin-6 dye as an indicator. The purified product 
(~200 mL volume) was precipitated from ether and collected by centrifugation at 1950 × g for 10 
min. The resulting pellet was lyophilized (Labconco Freezone 2.5, Kansas City, MO, USA) for two 
days and yielded a light yellow powder. Covalent linkage of FA to DSPE-PEG2000-NH2 was 
confirmed by 1H-NMR (Bruker Avance III HD, 500 MHz in deuterated DMSO). The final DSPE-
PEG2000-FA conjugate was stored at 4 °C  
2.2.3 Production of EuCF-DTG “core-shell” nanoparticles 
EuCF nanoparticles of 7.2 nm size were fabricated using solvothermal techniques [223] 
and characterized for hydrodynamic size, size distribution, shape, structural configurations, 
morphology, chemical composition and superparamagnetic properties. EuCF-DTG “core-shell” 
nanoparticles were synthesized using a modified solvent evaporation process [213, 224]. 
Specifically, PCL (400 mg), DTG (30 mg) and EuCF (20 mg) were dissolved in DCM, methanol 




(50 mg), mPEG2000-DSPE (25 mg) and DOPE (25 mg) in 5 mL of chloroform by bath sonication. 
A EuCF-DTG primary emulsion was prepared by mixing EuCF, PCL and DTG solutions with 
stirring for 6-8 h at 140 × g at room temperature. The secondary emulsion and shell layers for core 
nanoparticles were prepared by making a thin film of lipids (PC, PEG2000-DSPE and DOPE) in a 
round bottom flask through rotary evaporation (Büchi Rotavapor R-II, New Castle, DE, USA) of 
chloroform followed by overnight vacuum-drying. The primary emulsion of EuCF-DTG was then 
transferred into 30 mL of freshly prepared 1% (w/v) PVA and mixed by probe sonication (Cole-
Parmer, Vernon Hills, IL, USA) at 20% amplitude for 10 min in an ice bath. The PVA served as a 
surfactant in this emulsification step. The core nanoparticles were then transferred into the flask 
containing the lipid film. The flask was steadily rotated with the core nanoparticles in a bath 
sonicator followed by probe sonication at 20% amplitude for 10 min in an ice bath. Evaporation of 
DCM was carried out under pressure at 35°C followed by overnight stirring. The nanoparticles 
were purified by centrifugation of the suspension at 55 × g for 10 min, followed by centrifugation 
of the supernatant at 35,1315 × g for 30 min at 10°C (Sorvall, Lynx-4000 super speed centrifuge, 
Thermo Fisher Scientific, Waltham, MA, USA). The pellet was washed twice with PBS, 
resuspended in PBS and stored at 4°C. For preparation of FA-EuCF-DTG nanoparticles, 25 mg of 
DSPE-PEG2000-FA was used and the remainder of the synthesis followed the preparation of the 
EuCF-DTG nanoparticles. For drug quantification from nanoparticles, ~30 mg of lyophilized 
nanoparticles was dissolved in 10 mL of DCM: methanol (1:1 v/v) mixture. The mixture was then 
bath sonicated for 30 min followed by centrifugation at 35,1315× g for 30 min. The supernatant 
was collected and DCM was evaporated at room temperature. The drug in methanol was quantified 
by HPLC. 
2.2.4 Nanoparticle characterization 
Powder X-ray diffraction (XRD) analysis was carried out in the 2θ range of 2–70° using a 




radiation (1.5418 Å) at 40 kV and 45 mA. A mask of 20 mm and divergence slit of 1/32° were used 
on the incident beam path. A thin layer of the powdered nanoparticle was placed on a zero-
background silicon plate and continuously spun at a rate of 22.5°/s. The solid state PIXcel3D 
detector (PANalytical, Inc.) was scanned at a rate of 0.053°/s. The PIXcel3D was equipped with a 
beam monochromator to improve the signal-to-noise ratio. Magnetic characterization was 
performed using a superconducting quantum interference device (SQUID) magnetometer 
(Quantum Design, MPMS-XL, Quantum Design International (QDI), San Diego, CA, USA) at 300 
K. Stability of the EuCF-DTG nanoparticle suspension was assessed over three weeks by 
measuring hydrodynamic diameter and nanoparticle size distribution in saline on a Malvern 
Zetasizer Nano-Series instrument (Malvern Instruments Ltd., Malvern, UK) at 4 °C. FTIR were 
recorded on a Perkin-Elmer-spectrum attenuated total reflectance (ATR)-FTIR equipped with a 
UATR-accessary (Perkin-Elmer, Inc., Waltham, MA, USA). Atomic-force microscopy (AFM) was 
conducted using a Bruker Dimension Icon® Atomic Force Microscope (Bruker, Billerica, MA, 
USA) equipped with peak-force tapping and scan-assist with Al reflection coating (spring constant 
is 0.4 N/m and tip radius is ~2 nm, width 25 μm, thickness 0.65 μm, and length 115 μm). Multilayers 
of nanoparticles were prepared by drop-casting diluted aliquots of aqueous nanosuspensions on 
clean glass slides followed by slow evaporation of the solvent at room temperature. The images 
were flattened using Nano-Scope Analysis software (Bruker, Billerica, MA, USA). Nanoparticle 
morphology and structure were analyzed by transmission electron microscopy (TEM). 
Nanoparticle suspensions were dried on a copper grid at room temperature and bright field images 
were taken with exposure times of 2 s using the Tecnai G2 Spirit TWIN electron microscope (FEI, 
Houston, TX, USA) operating at 80 kV. Images were acquired with an AMT digital imaging 
system. Fluorescence spectroscopy was performed by SpectraMax® M3 Multi-Mode Microplate 
Reader (Molecular Devices, LLC, Sunnyvale, CA, USA). 




In vitro release study of DTG was performed using a USP dissolution testing system 
(Sotax-AT7smart USP, SOTAX Corp. Westborough, MA, USA) with dialysis bag technique [225] 
(Dialysis bag, MWCO 25 kD, Spectrum Laboratories, Inc., CA,USA). The DTG release 
experiments were carried out in Dulbecco’s phosphate-buffered saline (DPBS; Thermo Fisher 
Scientific, Waltham, MA, USA) with 2% (v/v) Tween-80. Five mg of DTG in EuCF nanoparticles 
were placed in dialysis bags containing 3 mL of the release medium. The bags were placed in 
stainless steel baskets and immersed in a container containing 1000 mL of release medium at a 
temperature of 37±0.5 °C. One mL of each sample was withdrawn at regular time intervals and the 
same volume was replaced with fresh release medium. Samples were further diluted and analyzed 
for DTG content by HPLC. These studies were performed in triplicate for each sample, and the 
average values were used in the data analyses. Furthermore, the release profiles of DTG from 
nanoparticles were each fitted with Higuchi, Korsmeyer–Peppas, Elovich equation, parabolic 
diffusion, Bhaskar-equation, and Modified-Freundlich mathematical models [226]. 
2.2.6 Isolation of culture of monocyte-derived macrophages (MDM) 
Human peripheral blood monocytes were obtained by leukapheresis from hepatitis B and 
HIV-1/2 seronegative donors, and purified by counter-current centrifugal elutriation [223]. Cells 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Grand Island, NY, 
USA) with 10% heat-inactivated pooled human serum (Innovative Biologics, Herndon, MA, USA), 
1000 U/mL macrophage colony stimulating factor, 1% glutamine, 50 μg/mL gentamicin, and 10 
μg/mL ciprofloxacin for 7 days to promote monocyte macrophage differentiation [227]. Cellular 
uptake of the EuCF-DTG and FA-EuCF-DTG nanoparticles was determined in MDM cultured in 
12-well plates at a density of 1.5 × 106 cells/well. Cells were treated with nanoparticles in medium 
at a concentration of 5 μg iron/mL for 12 h. Nanoparticle uptake was assessed by measurement of 
cell drug and iron concentrations without medium changes. Adherent MDM were scraped into PBS 




°C and briefly sonicated in 100 μL of a mixture of methanol:acetonitrile (1:1 v/v) then centrifuged 
again at 10,844 × g for 10 min at 4 °C. Supernatant was used for DTG quantification by reversed 
phase HPLC. Parallel sets of cells were collected into nitric acid (69%) for ICP-MS analysis of iron 
and cobalt content. 
2.2.7 Immunocytochemistry and transmission electron microscopy (TEM)  
Macrophage nanoparticle uptake and subcellular distribution were studied by confocal 
microscopy and TEM [207, 223, 228]. To determine subcellular localization of EuCF-DTG 
nanoparticles, MDM were treated with nanoparticles at a concentration of 5 μg iron/mL for 8 h. 
For immunofluorescence staining, cells were washed three times with 1 mL of PBS (10 min each 
step) and fixed with ice cold 4% paraformaldehyde (PFA) at room temperature for 30 min. The 
cells were then washed with PBS (1 mL, 3X) for 10 min at each step and treated with a 
permeabilizing reagent (0.5% v/v Triton-X-100) for 15 min at room temperature. Cells were again 
washed with PBS (1 mL, 3X) for 10 min at each step. Cells were treated with a blocking solution 
(5% w/v BSA in PBS and 0.1% v/v Triton-X-100) for 1 h at room temperature and quenched with 
50 mM NH4Cl for 15 min. The cells were washed once with 0.1% Triton-X-100 in PBS and 
incubated with primary antibody (Rab7 (SC-10767) for late endosomes, Rab11 (SC-6565) and 
Rab14 (SC-98610; Santa Cruz Biotechnology, Dallas, TX, USA) for recycling endosomes and 
LAMP-1 (NB120-19294; Novus Biologicals, Littleton, CO, USA) for lysosomes) diluted in 
blocking solution (5% BSA and 0.1% Triton-X in PBS; antibody: blocking solution 1:25) overnight 
with shaking at 4 °C. Cells were then incubated with secondary antibody (AlexaFluor-594; 
Thermo-Fischer Scientific, Waltham, MA, USA) and diluted in blocking solution (1:50) for 2 h at 
room temperature. Slides were covered with ProLong Gold AntiFade reagent with DAPI (4′,6-
diamidino-2- phenylindole; Thermo-Fischer Scientific, Waltham, MA, USA) and imaged using a 
63X oil objective on an LSM 710 confocal microscope (Carl Zeiss Microimaging, Inc., Dublin, 




number of pixels and the mean intensity of each channel. For TEM analysis, MDM (1.5 × 106 
cells/mL) were incubated in 12-well plates for 8 h with nanoparticles (5 μg/mL of iron 
concentration). After treatment, cells were centrifuged at 1950 × g for 10 min at 4 °C. Cell pellets 
were suspended in a solution of 2% glutaraldehyde and 2% PFA in 0.1 M Sorenson’s phosphate 
buffer (pH 6.2) for a minimum of 24 h at 4 °C. The cell fixation and block preparation methods are 
available in the Supplementary Material. MDM internal morphology was analyzed by cutting thin 
sections of control and nanoparticle-loaded MDM using a Leica UC6 ultramicrotome (Leica 
Microsystems, Inc., Buffalo Grove, IL, USA) then placed on 200 mesh copper grids. MDM and 
nanoparticle samples were examined using the Tecnai G2 Spirit TWIN electron microscope (FEI, 
Houston, TX, USA) operating at 80 kV. Images were acquired with an AMT digital imaging 
system. 
2.2.8 Antiretroviral activity  
Antiretroviral efficacies of the EuCF-DTG and FA-EuCF-DTG nanoparticles in HIV-1 -
infected MDM were evaluated as described [196, 229]. In brief, MDM were treated with 6.25 µM, 
12.5 µM, or 25 µM (DTG content) of native DTG, EuCF-DTG or FA-EuCF-DTG nanoparticles 
for 8 h. Cells were then cultured in fresh medium without nanoparticles. At days 1 and 5 post-
treatment, MDM were then treated with HIV-1ADA for 16 h at a multiplicity of infection (MOI) of 
0.1 infectious virions per cell. Cells were maintained for 10 days post infection with a full media 
exchange occurring 2 days prior to analysis. The culture supernatants were assessed for progeny 
virion formation by measuring reverse transcriptase (RT) activity [230]. At this time, cells were 
washed with PBS and fixed in 4% PFA for 15 min. Fixed cells were blocked using 10% BSA 
containing 1% Triton-X 100  
2.3 Results 




Theranostic multimodal EuCF-DTG lipid-PCL “core shell” nanoparticles were synthesized 
to have fluorescence, exhibit paramagnetism for MR imaging, and to package ARV therapy as 
lipid-PCL “core-shell” nano-constructs have previously been shown to be effective vehicles. 
Characterization of FA-decorated EuCF-DTG nanoparticles is outlined in Figure 2.1A 
Composition of the cores of the nanoparticles was PCL:DTG:EuCF (1:0.075:0.05 w/w/w) 
surrounded by a lipid shell of PC:DSPE-PEG:DOPE (1:0.5:0.5 w/w/w). For FA-EuCF-DTG 
nanoparticles, a lipid ratio of PC:DSPE-PEG2000-FA:DOPE (1:0.5:0.5 w/w/w) was used. 
Synthesized theranostic nanoparticles exhibited fluorescence and emission wavelengths at 410 nm 
and 660 nm, respectively. Transmission electron microscopy (TEM) determined the internal 
morphology of the nanoparticles, with TEM images in Figure 2.1B showing nanoparticles 
possessing a spherical shape with a core structure composed of the PCL surrounded by multiple 
lipid surface layers. TEM images of nanoparticles without EuCF are shown in Figure 2.1B (i-ii). 
Complete embedding of the EuCF within the PCL core matrix is illustrated in Figure 2.1B (iii-iv). 
Characterization of the surface topography of nanoparticle was performed using atomic force 
microscopy (AFM) and suggested the lipid layers covered the spherical nanoparticles with smooth 
and uniform surfaces, as shown in Figure 2.1C. X-ray diffraction (XRD) patterns of EuCF and 
EuCF-DTG are shown in Figure 2.1D. Comparison of diffractograms of EuCF-DTG with that of 
native EuCF confirmed polycrystalline nature of the theranostic nanoparticles. Furthermore, XRD 
diffractogram patterns of the EuCF-DTG nanoparticles displayed peaks corresponding to organic 
and inorganic EuCF phases, showing incorporation of all necessary components into a finalized 
nanoparticle. Diffraction peaks exhibiting a decrement in EuCF intensity do so because of the 
masking effect of both PCL and lipids [231]. Broader diffraction peaks present in the EuCF-DTG 
XRD were attributed to the to the presence of nanosized EuCF crystals [231]. EuCF-PCL 
nanoparticles showed a saturation magnetization value of 7.5 emu/g and a sigmoid curve via 
superconducting quantum interference device (SQUID) analysis shown in Figure 2.1E, 




scattering (DLS) was utilized to determine the hydrodynamic size of monodispersed nanoparticles, 
as shown in Figure 2.1F. Average nanoparticle size was 253 nm in diameter with a polydispersity 
index (PDI) of 0.14 and ~6.2% w/w DTG drug loading. Drug release from theranostic EuCF-DTG 
nanoparticles  was found to cumulative with ~30% of drug released within 5 days and 36% by day 
10 as shown in figure 2.1G. Additionally, it was found that when the cumulative percentages of 
DTG release from experimental formulations was plotted vs time that ~40% of DTG was released 
in 12 days from EuCF-DTG. Several kinetic models were used to better understand mechanism of 
DTG release from the EuCF-DTG nanoparticles: experimental in vitro release data set was fitted 
by the Higuchi, Korsmeyer-Peppas, parabolic diffusion, Elovich equation, Bhaskar equation, and 
a Modified-Freundlich kinetic model [225, 226]. Of the kinetic models tested, the parabolic 
diffusion and Bhaskar equations showed a theoretical DTG release pattern that was close to the 
experimental profile. Therefore, the kinetics of DTG release are governed by diffusion-controlled 
release phenomena.   
Theranostic nanoparticles with a folic acid (FA) receptor targeting ligand were prepared 
by incorporating FA-PEG-DSPE onto the surface of EuCF-DTG nanoparticles. Specifically, 
chemical shifts at 3.3-3.6 ppm in the 1H-NMR spectrum correspond to repeating ethylene oxide 
(CH2CH2O) hydrogens of the PEG component of the lipid, while the aromatic protons from FA 
are at 7.7 and 8.3 ppm. Chemical shifts corresponding to DSPE are seen at 0.9 ppm (-CH3), 1.1 
ppm (-CH2) and 2.1 ppm (-CH2CO) [40]. The EuCF nanoparticles contain characteristic 
absorption bands of octahedral metal-oxygen (M–O) bonds of the ferrite lattice [21]. DTG showed 
characteristic absorption bands at 1272 (-C-N), 1588 and 1650 (-C=O), 2983 (-C-H) and 3082 cm-
1 (-C-H aromatic rings). The IR spectrum of PC demonstrates a characteristic C=O stretching band 
at 1740 cm−1 and PO−2 asymmetric double bond stretching bands at 1250 cm−1. The spectra of 
both PEG–DSPE and PC demonstrate a carbonyl ketone band at 1740 cm−1 and a CH alkyl-




belonging to EuCF, DTG, PCL and lipids, along with bands at 2951 cm−1 (asymmetric), 2873 cm-
1 (symmetric) due to (−CH2), and 1725 cm-1 for the carbonyl (−C=O) stretching of PCL [213]. The 
FTIR results indicate that DTG and EuCF interact strongly with PCL and lipids. 
2.3.2 Macrophage uptake and subcellular distribution  
Cellular uptake of theranostic nanoparticles was determined in MDMs. Cells were treated 
with FA-EuCF-DTG or EuCF-DTG nanoparticles (based on 5 µg/ mL iron) for up to12 hours, with 
cells washed in phosphate-buffered saline (PBS) and collected into nitric acid (69.0%) at either 2,4, 
8, or 12 hours post-treatment. Cobalt and DTG concentrations were determined by ICP-MS and 
UPLC-MS/MS, respectively. As shown in Figure 2.2A, the uptake of FA-EuCF-DTG nanoparticles 
was significantly greater than that of EuCF-DTG nanoparticles at both 8 hours and 12 hours, as 
determined by iron content analysis. Cell iron concentrations exhibited a 4.5-fold greater amount 
of iron in cells treated with FA-EuCF-DTG nanoparticles are compared to EuCF-DTG 
nanoparticles at 12 hours post treatment. Cellular DTG levels show results corresponding to iron 
levels, with Figure 2.2B exhibiting FA-EuCF-DTG nanoparticles providing higher amounts of drug 
compared to EuCF-DTG nanoparticles. Visualization of cellular uptakes of nanoparticles and their 
subsequent subcellular distribution was performed using confocal microscopy and the inherent 
fluroscent properties of Eu3+ within nanoparticles (Figure 2.2C). Specifically, subcellular 
distribution of EuCF-DTG nanoparticles was determined by immunostaining with various different 
endosomal protein antibodies: Rab7 representing late endosomal sorting, Rab11 and Rab14 
representing recycling endosomal compartments, and LAMP-1 representing the lysosomal-
associated membrane protein-1. Primary antibodies were detected using a red Alex Fluor 594 
secondary antibody. Figure 2.2D shows the yellow color associated with the colocalization of 
EuCF-DTG nanoparticles (green) and endosomal proteins (red) [196]. These resulting images 
suggest that EuCF-DTG nanoparticles were distributed mainly in recycling endosomal 




Distribution within lysosomal regions (LAMP-1) and early endosomal compartments (Rab7) was 
less than that seen in recycling endosomes. Additionally, TEM was used to investigate the 
subcellular distribution of nanoparticles (Figure 2.2F-H) Typical macrophage morphology is 
illustrated by TEM of a control cell in Figure 2.2E, and visually there appears to be a greater amount 
of FA-EuCF-DTG nanoparticles that were internalized as compared to EuCF-DTG. Macrophage 
morphology was not altered by the presence of theranostic nanoparticles.  
2.3.4 Antiretroviral activities of EuCF-DTG and FA-EuCF-DTG nanoparticles.  
MDM infected with HIV-1ADA, a prototype macrophage-tropic strain, were used to assess 
the antiretroviral activities of EuCF-DTG and FA-EuCF-DTG nanoparticles [196]. MDM were 
treated with nanoparticles are various DTG concentration while native drug served as a control. 
MDM were infected at a multiplicity of infection (MOI) of 0.1 infectious viral particles per cell 
after 1 day post-treatment. Progeny HIV-1 virion production was determined by reverse 
transcriptase (RT) activity in cell culture fluids 10 days after infection, with intracellular p24 
antigen expression also being measured within cells. Figure 2.3A Illustrates that RT activity was 
suppressed by 6.25, 12.5, and 25 µM DTG (both native and nanoparticles), with parallel results 
being displayed in HIV-1 p24 staining (Figure 2.3B). Fewer HIV-1 p24 positive cells  were detected 
with EuCF-DTG and FA-EuCF-DTG nanoparticles than in cell treated with native DTG at day 1 
after treatment.  
2.4 Discussion  
The use of LASER ART as a viable alternative to conventional ARV therapy has been 
realized in our laboratories previous publications [195, 199, 202, 232, 233]. LASER ART can affect 
regimen changes, improve patient ARV adherence, reduce systemic toxicities, ease pill burdens 
and limit new viral infections [201, 233-235]. Nonetheless, hurdles remain in the conversion from 
commonly used pills into long-acting drug formulations. Our laboratories have taken a singular 




using decorated polymers to target reservoirs of viral infection. This strategy seeks to optimize drug 
delivery, biodistribution and PK profiling [195-197, 199, 229]. However, the best strategy to screen 
newly synthesized and decorated nanoparticles remains unrealized. As therapeutic success of 
formulations is linked to nanoparticle size, shape, decoration, encapsulation and drug half-life, 
screening is cumbersome. Moreover, how best to assess drug penetrance into “putative” viral 
reservoirs remains a major obstacle in translational research efforts. We now posit that one means 
to assess the therapeutic potential of LASER ART is through theranostic probes [223]. Thus, stable 
ultra-sensitive EuCF nanoparticles encapsulating ARV and surrounded by lipids [213] were made. 
Such theranostic screens used to assess cell-based drug delivery holds potential for approaches to 
develop eradication strategies to cure HIV-1/AIDS. 
EuCF-DTG nanoparticles were prepared via an emulsification solvent evaporation method 
using dichloromethane (DCM) as the organic phase. The mechanism of formation of 
multicomponent nanosystems is described as a combination of inorganic nanoparticles (EuCF) and 
organic, hydrophobic, biodegradable PCL forming the core of the particles with amphipathic lipids 
(DOPE, mPEG2000-DSPE and PC) constituting the shell of the multicomponent nanosystems. 
Importantly, PCL has a good solubility in DCM, which by diffusing towards the oil phases 
enhances the hydrophobic drug (DTG) retention in the core of EuCF-PCL, significantly improving 
encapsulation efficiency. Additionally, when the EuCF-PCL and drug solution (in DCM) is 
dispersed into the aqueous polyvinyl alcohol (PVA) surfactant, the agitation of the interface 
spontaneously produces a bigger interfacial area, which leads to nano-sized quasi-emulsion 
droplets of EuCF and DTG encapsulated in PCL. Simultaneously, combinations of amphipathic 
lipids serve as secondary surfactants on the surface of nanoparticles. Meanwhile, methanol 
specially diffuses from droplets due to its lower affinity for EuCF, DTG and PCL, and higher 
affinity for PVA. Continuous diffusion of methanol out of the droplets and the coacervation of PVA 




Conclusively, the evaporation of residual solvent and subsequent solidification of EuCF-DTG core-
shell nanoparticles, together with stirring in PVA solution, caused greater reduction in surface 
tension, leading to formation of the resultant particles in the nanometer range and with spherical 
morphologies. 
DTG was released slowly over a time period of 12 days. The prolonged release profile 
could be attributed to physicochemical properties of the EuCF-DTG core-shell. Drug release 
occurred by diffusion through the lipid barriers followed by erosion of the core polymer by 
hydrolytic degradation. These hypotheses were cross validated by kinetic parabolic diffusion and 
Bhaskara equation models indicative of the low permeability of water in the particle’s interior PCL 
core-shell. Due to the hydrophobic nature of DTG, it is probable that the drug was incorporated at 
the core of the particles during the solvent evaporation process. It is expected that nanoparticles 
prepared by solvent evaporation slowly release the drug due to the hydrophobic nature of the core 
materials. 
Macrophage uptake and subcellular nanoparticle distribution enables drug delivery to HIV-
1 infection sites [13, 236, 237]. Uptake of the lipid nanoparticles is greater than that of silica 
platforms [223]. The fluorescence modality of the EuCF-DTG and FA-EuCF-DTG nanoparticles 
proved useful in identifying nanoparticle subcellular distribution. We assayed macrophage 
nanoparticle uptake by measurements of both iron and DTG. We then examined nanoparticle 
subcellular localization using antibodies specific to subcellular compartment proteins and showed 
that the nanoparticles were distributed preferentially within recycling endosomes. Previously, we 
and others have demonstrated preferential localization of nanoformulated rod-shaped nanoparticles 
containing ARV drugs in similar compartments [196, 229]. HIV-1 persists in recycling endosomes 




Overall, EuCF-DTG “multimodal imaging theranostic nanoprobes” were made to facilitate 
the development of targeted LASER ART. The lipid-encapsulated EuCF nanoparticles can fulfill 










































Figure 2.1 Synthesis and characterization of lipid-coated core-shell nanoparticles. (A) A 
schematic illustration of the design of multimodal FA-EuCF-DTG core-shell nanoparticles is 
presented. (B) TEM images of nanoparticles, (Bi) PCL-DTG (without EuCF) nanoparticles, (Bii) 
FA-functionalized PCL-DTG (without EuCF) nanoparticles, (Biii) EuCF-DTG nanoparticles, and 
(Biv) FA-EuCF-DTG nanoparticles. The lipid layers (average thickness of ~15 nm) appeared as a 
solid corona around the “hard” PCL matrix. EuCF nanocrystals (red arrows) appear as crystalline 
hexagonal-shaped monodispersed structures in the PCL matrix. (C) Characterization of the size 
distribution of EuCF-DTG nanoparticles by AFM. (Ci) AFM topographic distribution of EuCF-
DTG nanoparticles and, (Cii) a corresponding 3D view. (D) X-ray powder diffraction (XRD) 
patterns of EuCF and EuCF-DTG nanoparticles. (E) Evaluation of the magnetic properties of the 
nanoparticles by magnetic-hysteresis (M-H) curves measurements using SQUID. Data are recorded 
at 300 K. (F) Hydrodynamic size distribution of nanoparticles determined by dynamic light 
scattering (average nanoparticle size of ~253 nm) and (G) in vitro release profiles of DTG in PBS 




















Figure 2.2 Macrophage nanoparticle uptake and subcellular distribution. Uptake and 
subcellular distribution of nanoparticles was determined in human MDM (monocyte-derived 
macrophage). EuCF-DTG and FA-EuCF-DTG nanoparticles were detected in cells at 2 h. EuCF-
DTG and FA-EuCF-DTG nanoparticles were added to MDM culture at a concentration of 5 μg/mL 
iron. (A) Iron concentrations in MDM following nanoparticle uptake over 12 h and (B) 
corresponding DTG levels; data represent mean ± SEM (n = 3). Statistical differences were 
determined using one-way ANOVA among groups followed by Student’s t-test for differences 
between groups at each time-point, ****p < 0.0001. (C) Intracellular nanoparticles were detected 
by confocal microscopy at an excitation wavelength of 488 nm and emission wavelength of 
510/520 nm. (D) For subcellular distribution analysis, MDM were treated with EuCF-DTG 
nanoparticles (5 μg/mL based on iron; green) for 8 h and then immunostained with Rab7, Rab11, 
Rab14 and LAMP-1 antibodies and Alexa Fluor 594-labeled secondary antibody (red) to visualize 
nanoparticle and organelle co-registration. The yellow (merged) shows overlap of nanoparticles 
and Rab compartments. DAPI (blue) stain indicates cell nuclei. Images were captured with 63X 
objective on a Zeiss LSM 710 confocal microscope. Scale bars = 20 μm. (E-H) TEM ultrastructural 
evaluation of macrophage nanoparticle uptake and subcellular distribution. Nanoparticles were 
added to MDM cultures for 8 h. Cells were fixed and processed for TEM. (E) Typical internal 
morphology of control macrophages is shown. Detailed evaluation of membrane-bound 
intracellular structures at areas of interest is presented in magnified panel ii and iii. (F–H) 
Intracellular uptake of (F) PCL-DTG (without EuCF), (G) EuCF-DTG and (H) FA-EuCF-DTG 
nanoparticles. Areas of interest bordered with dotted red lines are presented in corresponding high-
resolution images (ii–iii) and illustrate nanoparticles within membrane-bound intracellular 
structures. All nanoparticle types were internalized and entrapped in endosomal vesicles in the 
macrophages. Images of macrophages treated with FA-functionalized nanoparticles reveal a higher 
number of nanoparticles internalized in vesicles compared to non-decorated particles. EuCF-DTG 
and FA-EuCF-DTG nanoparticles are seen as black punctate structures encapsulated in white 











Figure 2.3 Antiretroviral activity measurements. Antiretroviral activity was determined in 
MDM treated for 8 h with free DTG, EuCF-PCL, EuCF-DTG or FA-EuCF-DTG nanoparticles 
(6.25, 12.5 and 25 μM DTG) and then infected with HIV-1ADA at a multiplicity of infection 
(MOI) of 0.1 at day 1 after drug loading. At 10 days after infection, progeny HIV virion 
production was determined by RT activity in the cell culture fluids. (A) HIV replication was 
determined 10 days after infection by HIV RT activity of day 1. Statistical differences were 
determined using one-way ANOVA among groups; we used Tukey’s test to correct for multiple 






In vivo and ex vivo biodistribution studies of multi-

















3.1 Introduction  
To realize the potential of long acting viral reservoir penetrating drugs, pharmacokinetic 
and pharmacodynamic profile assessment must be performed to minimize on and off-target effects. 
Current PK and PD experimental assessments often take weeks to months to perform, and with 
multiple innovative strategies coming to the forefront of development, such timeframes have 
proved too tedious and time consuming. To overcome these technical and biologic challenges, 
multimodal decorated nanoparticles were produced where hydrophobic ARVs and bioimaging 
agents were encased in a single nanoformulation. All were placed into one “multimodal imaging 
theranostic nanoparticle” using core-shell construction methods [213]. This allowed real-time 
assessment of ARV biodistribution and activity [223]. Synthesized nanoparticles were deployed for 
sensitive MRI tests. Such testing facilitated PK analyses and monitoring of drug-loaded 
nanoparticle distribution into tissue reservoirs of viral infection. The core-shell structure was 
engineered to carry ARVs that include DTG (EuCF-DTG), while demonstrating excellent 
relaxivity profiles of r2 = 564 mM-1 s-1 and r2 = 546 mM-1 s-1 (targeted nanoparticles) in saline and 
r2 = 876 mM-1 s-1 and r2 = 850 mM-1 s-1 (targeted nanoparticles) in cells. The Eu3+ component 
enabled fluorescence imaging for histological validation of cell localizations of drug-loaded 
nanoparticles [223]. DTG release from EuCF-DTG nanoparticles provided real-time validation of 
drug biodistribution, as EuCF-DTG nanoparticles are rapidly endocytosed and retain potent 
antiretroviral activity. Confocal microscopy with Eu3+ fluorescence showed nanoparticles in 
cytoplasmic Rab compartments that affect vesicle trafficking and ARV depot formation [195, 202, 
238, 239]. Following synthesis and particle characterization, bioimaging tests reflected drug 
biodistribution after parenteral injection in rats and rhesus macaques. No secondary metabolic or 
histopathological alterations were observed. 
3.2 Materials and methods  




EuCF-DTG and FA-EuCF-DTG nanoparticle suspensions with an iron concentration 
ranging from 0.2 to 2 μg/mL were prepared in DPBS. A 1.5% w/v agar gel was prepared by adding 
150 mg of low melting agar in 10 mL of PBS at 70°C for 30 min. Phantom gels containing 
nanoparticles were prepared by mixing 100 μL of a 1.5% (w/v) agar solution that was preheated to 
60°C to prevent gelation with 100 μL of the nanoparticle suspension. Experiments were performed 
in triplicate at each concentration. In order to make sure that no air bubbles were present, the 
nanoparticle suspensions and agar gels were vortexed thoroughly while warm in 250 μL eppendorf 
tubes and then rapidly cooled in an ice bath. MRI tests were performed using eppendorf tubes 
containing the fixed nanoparticles in agar gels. MRI data were acquired on a 7T/16 cm Bruker 
PharmaScan MRI system (Bruker; Ettlingen, Germany). T2-relaxtion maps were generated using 
a CPMG (Carr Purcell Meiboom Gill sequence) phase-cycled multi-echo sequence. Single slice 
(0.5 mm slice thickness) data were acquired with 3000 ms repetition time, 50 echoes (echo times 
TEn = n x 10 ms; n = 1), 256 x 128 acquisition matrix, 50 x 50 mm field of view (FOV), 2 averages, 
for a total scan time of 13 min. For T2 relaxation time measurements in MDM, as described in our 
previous study [223], monocytes were seeded onto 100 mm culture plates at a concentration of 106 
cells/mL and differentiated into macrophages in the presence of MCSF for seven days. Following 
this, MDM were treated with nanoparticles (5 µg iron/mL) for 8 h and then the treatment medium 
was removed and cells washed three times with DPBS. Cells were scraped into DPBS, collected 
by centrifugation (1950 × g for 10 min at 4 °C) and suspended at various cell concentrations 
containing 1.5% w/v agar in 250 μL eppendorf tubes. For T2 map measurements, CPMG phase-
cycled 3-dimensional multi-echo sequence data was acquired with 250 ms repetition time, 48 
echoes (echo times TEn = n X 2.618; n = 1,…,48), 128 × 128 × 64 acquisition matrix, 70 × 64.76 
× 42.38 mm FOV, one average, for a total scan time of 34 min. 




In vivo biodistribution of nanoparticles was determined in male Sprague Dawley rats (160–
170 g) obtained from Charles River Laboratories (Wilmington, MA, USA). Animals were housed 
in the University of Nebraska Medical Center (UNMC) laboratory animal facility according to 
Association for Assessment and Accreditation of Laboratory Animal Care guidance. All protocols 
related to animal experiments were approved by the UNMC Institutional Animal Care and Use 
Committee, and met the requirements of the UNMC ethical guidelines set forth by the National 
Institutes of Health. Rats were divided into multiple groups dependent on their route of injection 
and planned sacrifice time point of 2, 5, or 10 days post-injection. 24 hours prior to nanoparticle 
treatment, rats were given 5 mg/kg lipopolysaccharide (LPS) by intraperitoneal injection to engage 
the innate immune system and affect macrophage activation in analogous manners as would be 
seen following HIV-1 infection. Rats were MRI scanned prior to injection of the EuCF-DTG 
nanoparticles (2 mg iron/kg iron content) and at 2, 5 and 10 days post-injection to determine 
nanoparticle biodistribution and integrity. Assessment of the effects of FA targeting was performed 
by administration of FA-EuCF-DTG nanoparticles in rats by either IM or IV injection. MRI 
scanning was performed pre-injection and 5 days after injection for comparison tests of EuCF-DTG 
administered animals. MRI was performed using the same 7T/16 cm Bruker PharmaScan that was 
used for phantom data acquisition. Both T2 ∗-weighted high-resolution imaging and T2 mapping 
were used to determine the biodistribution of EuCF-DTG nanoparticles. T2 ∗-weighted MRI was 
performed using a 3D spoiled gradient recalled echo sequence with 10 ms repetition time, 2.7 ms 
echo time, 15° pulse angle, 256 × 196 × 128 acquisition matrix, 75 × 57.5 × 37.5 mm FOV, six 
averages, for a total scan time of 25 min. For T2 mapping, CPMG phase-cycled 3-dimensional 
multi-echo sequence data were acquired with 24 echoes (echo times TEn = n × 2.718 ms; n = 1, 2, 
…,24), 400 ms repetition time, 128 × 128 × 64 acquisition matrix, 70 × 64.76 × 42.38 mm FOV, 
one average, for a total acquisition time of 34 min. T2 relaxation times were computed at each pixel 
and generated maps using custom computer programs written in Interactive Data Language (IDL; 




injection and 24 h post-injection of nanoparticles using the even-echo images from the CPMG 
phase cycled imaging data. Estimation of T2 relaxation times from even echoes only minimizes the 
measurement errors due to the imperfection of high-power pulses [240]. The region of interest 
(ROI) analysis was performed using Image-J software (http://imagej.nih.gov/lj). The 
concentrations of nanoparticles were determined from the change in relaxivity rate (ΔR2 = 
1/T2postinjection − 1/T2preinjection) and the nanoparticle relaxivity (r2) per mmol was 
determined as the slope of iron concentration versus R2 measured ex vivo 
3.2.3 Plasma and tissue drug, iron, and cobalt animal tissue quantifications  
Drug concentrations in animal plasma and tissues were determined by UPLC-tandem mass 
spectrometry (UPLC-MS/MS) using a Waters Acquity H-class UPLC- Xevo TQ-S micro system 
(Waters Corp, Milford, MA, USA). For plasma drug quantitation, 25 μL of sample was added into 
1 mL acetonitrile, followed by addition of 10 µL of internal standard (IS) solution to achieve a final 
IS concentration of 50 ng/mL DTG-d3 (Clearsynth Canada Inc, Mississauga, ON, Canada) after 
reconstitution. Samples were then vortexed and centrifuged at 17,000 g for 10 min at 4°C. 
Supernatants were dried using a Thermo Scientific Savant Speed Vacuum (Waltham, MA) and 
reconstituted in 100 µL 50% (v/v) acetonitrile in MS-grade water. Standard curves were prepared 
in blank rat plasma in the range of 0.2–00 ng/mL. For tissue analyses, 100 mg of tissue was 
homogenized in 4 volumes of 90% (v/v) acetonitrile in MS-grade water using a Qiagen Tissue 
Lyzer II (Valencia, CA, USA). To 100 µL of tissue homogenate 80 µL of acetonitrile, 10 µL of 
50% acetonitrile (v/v) was added in MS-grade water, and 10 µL IS. Standard curve samples were 
prepared using equivalent tissue matrix dilutions, 80 µL of acetonitrile, 10 µL of 50% acetonitrile 
(v/v) in MS-grade water spiked with standard drug concentrations, and 10 µL of IS. 
Chromatographic separation of 10 µL of plasma or tissue samples was achieved with an Acquity 
UPLC-BEH Shield RP18 column (1.7 µm, 2.1 mm x 100 mm) using a 10-min gradient of mobile 




and mobile phase B (100% Optima-grade acetonitrile) at a flow rate of 0.25 mL/min. The initial 
mobile phase composition of 40% B was held for the first 3 min, increased to 86% B over 0.5 min 
further, held constant for 5 min, then reset to 40% B over 0.25 min and held constant for 1.25 min. 
DTG was detected at a cone voltage of 10 volts and collision energy of 25 volts. Multiple reaction 
monitoring (MRM) transitions used for DTG and DTG-d3 were 420.075 > 277.124 and 422.841 > 
129.999 m/z, respectively. Spectra were analyzed and quantified by Mass Lynx software version 
4.1. DTG quantitations were based upon drug peak area to internal standard peak area ratios. Iron 
and cobalt levels were quantified by inductively coupled plasma mass spectrometry (ICP-MS) on 
an Agilent Technologies ICP-MS 7500cs (Santa Clara, CA) and an ESI SC-4 high-throughput 
autosampler (Elemental Scientific Inc., Omaha, NE) [241] 
3.2.4 SIV-infected rhesus macaques 
Three female rhesus monkeys were obtained from the Yerkes National Primate Research 
Center. The monkeys were infected with SIVmav239 by an intravenous injection route 350 days 
prior to drug administration. The monkeys had also been infected with Zika virus subcutaneously 
175 days prior to this study. All animals had cleared Zika virus but were productively chronically 
infected with SIV. EuCF-DTG nanoparticles were prepared under GLP conditions as above and 
given to animals by intramuscular injection at a dose of 2 mg/kg based on iron on day 0. Animal 
health was monitored daily and injection sites were examined closely under anesthesia on days 3 
and 7; no reaction was noted. Blood was collected in K-EDTA tubes and plasma prepared on day 
-5, day 0, day 3 and day 7; CSF was collected without additives in tubes on day 0 and day 7. On 
day -2 pre- and day 5 post- EuCF-DTG nanoparticle administration, MRI was performed on the 
three animals. 




Biodistribution of EuCF-DTG nanoparticles in rhesus macaques was determined using a 
Philips Achieva (Briarcliff Manor, NY, USA) 3.0T MRI scanner. T2-weighted high-resolution 
imaging and T2 mappings were obtained. High resolution T2-weighted images were acquired using 
a turbo spin echo (TSE) sequence with 1428.6 ms repetition time, 90 ms echo time, 90° flip angle, 
116 echo train length, 22 slices (3.5 mm slice thickness; 4.5 mm spacing between slices), 360 × 
360 acquisition matrix, 360 × 360 mm FOV, 6 averages, for a total scan time of 31.42 min. A multi-
echo TSE sequence was used for T2 relaxation time mapping. Images were acquired with 2000 ms 
repetition time, 16 echoes (echo times TEn = n x 6 ms; n = 1, …,16), 288 x 288 acquisition matrix, 
360 × 360 mm FOV. This sequence was repeated to cover multiple coronal slices (12 slices for pre-
injection and 16 slices for post-injection, 3.5 mm slice thickness, 4.5 mm spacing between slices). 
T2 relaxation time maps were created using custom-developed computer programs using IDL 
programming language. ROI analysis was performed using ImageJ software. 
3.2.6 Tissue analyzes from treated rhesus macaques 
After imaging on day 5, bone marrow and lymph node biopsies were performed on two of 
the animals. The third animal was sacrificed on day 7, and fluids and tissues were collected for 
study. At necropsy, splenomegaly and lymphadenopathy were present (consistent with chronic SIV 
infection), and EuCF-DTG nanoparticles were present in the gall bladder, confirmed by ICP-MS 
(cobalt = 0.476±0.037 μg/g). Complete blood counts and metabolic panels were performed by the 
UNMC Department of Pathology and Microbiology / Nebraska Medicine Clinical Laboratory 
Services. All animal experimentation was performed under approval by the UNMC IACUC in 
AAALAC-certified facilities following NIH guidelines 
3.2.7 Immunohistochemistry of rat tissues  
To determine cellular distribution of EuCF-DTG nanoparticles in tissues, following the 




collection of tissues. Tissues were fixed in 4% PFA overnight and embedded in paraffin. Tissue 
sections (5 µm) were cut and mounted on glass slides. For rats, tissues sections were probed with 
rabbit anti-rat polyclonal antibody to ionized calcium binding adaptor molecule-1 (Iba-1) (1:500; 
Wako Chemicals, Richmond, VA, USA) to detect macrophages. Primary antibody was detected 
with anti-rabbit secondary antibody conjugated to Alexa Fluor 594 (Thermo-Fischer Scientific, 
Waltham, MA, USA). 
3.2.8 Immunohistochemistry of rhesus macaque tissues 
Tissues (spleen and lymph nodes) were perfused with phosphate buffer saline (PBS) 
followed by post-fixation with 4% paraformaldehyde (PFA) for 3 days at room temperature then 
processed in a automated processor in Shandon Citadel-1000 processor (Thermo scientific) for 18 
h with reagents in step-wise manner containing 70, 95 and 100% flex followed by Xylene and 
paraffin. Finally tissues were embedded using paraffin blocks for further sectioning. Sections 5μ-
thick were cut from the paraffin blocks, mounted on glass slides and labelled with combination of 
rabbit monoclonal antibody to CD68 (Sigma-Aldrich, St. Louis, MO, USA) for macrophages and 
mouse monoclonal antibodies to SIV-p27. Primary antibodies were labeled with secondary anti-
mouse and anti-rabbit antibodies conjugated to the fluorescent probes Alexa Fluor® 633 and Alexa 
Fluor®594 and nuclei were labeled with 4′,6-diamidino-2-phenylindole (DAPI). Slides were cover 
slipped with ProLong Gold anti-fade reagent (Invitrogen, Carlsbad, CA), allowed to dry for 24 h at 
room temperature and then stored at −20 °C for future use. Images were captured at wavelengths 
encompassing the emission spectra of probes, with a 40X magnification objective. Images were 
captured using a Zeiss LSM710 confocal microscope and analyzed with Zen 2011 software (Carl 
Zeiss Micro imaging) 




In vivo toxicity of the EuCF-DTG nanoparticles was determined by serum chemistry and 
histological examination. For histological examination, 5 μm sections of paraffin-embedded tissues 
were affixed to glass slides and stained with hematoxylin and eosin. Images were captured with a 
20X objective using a Nuance EX multispectral imaging system affixed to a Nikon Eclipse E800 
microscope (Nikon Instruments, Melville, NY, USA). Histopathological assessment was conducted 
in accordance with the guidelines of the Society of Toxicologic Pathology. For serum chemistry 
analysis, rat blood samples were collected before and five days after EuCF-DTG nanoparticles 
administration. Albumin (ALB), alanine aminotransferase (ALT), total bilirubin (TBIL), phosphate 
(PHOS), total protein (TP) and amylase (AMY) were quantitated using a VetScan comprehensive 
diagnostic profile disc and a VetScan VS-2 instrument (Abaxis Veterinary Diagnostics, Union City, 
CA, USA). 
3.3 Results 
3.3.1 MRI assessment of EuCF-DTG and FA-EuCF-DTG nanoparticles biodistribution  
Theranostic nanoparticle relaxation rates (R2) were measured in both PBS and MDM and 
were found to increase linearly with increasing iron concentrations, demonstrating paramagnetism 
(Figure 3.1C). The linear regression coefficients of determination (r2) for relaxation rate (R2) vs. 
iron content for EuCF-DTG and FA-EuCF-DTG nanoparticles were 0.979 and 0.973 in PBS, 
respectively (Figure 3.1C left), and 0.985 for both EuCF-DTG and FA-EuCF-DTG nanoparticles 
in cells (Figure 3.1C right). The relaxivities of the EuCF-DTG and FA-EuCF-DTG nanoparticles 
were r2 = 564 mM-1 s-1  and r2 = 546 mM-1 s-1  in PBS, and r2 = 876 mM-1 s-1  and r2 = 850 mM-1 
s-1  in cells, respectively. In comparison with superparamagnetic iron oxide (SPIO) nanoparticles, 
FA-EuCF-DTG nanoparticles showed a log-order of magnitude increase in both sensitivity and 
specificity at replicate iron concentrations  [223]. T2*-weighted images of FA-EuCF-DTG 




intensities, again showing the paramagnetic properties of the synthesized nanoparticles (Figure 
3.1D). Together, these data confirmed magnetic sensitivity.  
In vivo assessment of EuCF-DTG and FA-EuCF-DTG nanoparticle biodistribution was 
performed in Sprague Dawley rats following either intravenous (IV) or intramuscular (IM) 
injection (Figure 3.3A).  The experimental timeline for the EuCF-DTG nanoparticle injection and 
MRI scanning is shown in Figure 3.2A.  MR images representative of pre-injection and 2,5, and 10 
days post-injection time points are shown in Figure 3.2B A reduction in T2*-weighted signal 
intensity in the MRI images can be seen within animals liver (red highlight) and spleen (green 
highlight) at all post-injection time points, reflecting the presence of iron due to nanoparticle 
distribution to these tissues.  
In vivo assessment of EuCf-DTG nanoparticle biodistribution was also performed in rhesus 
macaques infected with simian immunodeficiency virus (SIV). Administration of theranostic 
nanoparticles to these animals was proof-of-concept to determine subsequent biodistribution in a 
large animal during viral infection, such an animal model is much more comparable to humans 
infected with HIV-1. Plasma viral loads ranged from 106-107 copies/mL in the tested animals. 
Figure 3.3C shows a schematic of the uptake of EuCF-DTG nanoparticles by macrophages and the 
establishment of a reticuloendothelial system drug depot. MR images of rhesus macaques before 
nanoparticle injection and 5 days post-injection revealed a significant decrease in T2-weighted 
signal within the liver and the spleen after 5 days (Figure 3.3D). This change in T2 signal intensity 
proved to be higher within the liver as compared to the spleen, indicating a possible increase in 
uptake of EuCF-DTG nanoparticles within hepatic tissue. Such shortening of T2 in the rhesus 
macaque MR images are comparable to MR images taken of EuCF-DTG at identical timepoints, 
suggesting that EuCF-DTG biodistribution is similar between the species. 




 The concentrations of the various components of EuCF-DTG nanoparticles within 
administered animals was determined by multiple independent techniques: iron concentration was 
estimated in vivo by MRI, DTG drug concentration was determined ex vivo by ultraperformance 
liquid chromatography tandem mass spectrometry (UPLC-MS/MS), and cobalt concentration was 
determined ex vivo by inductively coupled plasma mass spectrometry (ICP-MS) (Figure 3.6A-C).  
Quantification of iron concentrations within the liver and spleen of both rats and rhesus macaques 
was performed by MRI T2 mapping, and subsequently compared with respect to time and route of 
administration (Figure 3.5A). Iron concentrations were two-fold higher in animals given IV 
injections compared to animals given IM injections (Figure 3.5A) IV injected animals displayed 
decreasing iron levels in the liver and spleen over time, while corresponding iron levels in IM-
injected animals were lower but sustained over the 10-day experimental time course. Comparison 
of tissue iron and cobalt levels exhibited a similar trend of DTG drug levels (Figure 3.5A-B).  
Figure 3.5C shows liver and spleen DTG concentrations at days 2 and 5. Figure 3.6 D-E illustrates 
cobalt and DTG plasma concentrations. Drug levels in liver and spleen were approximately 2-fold 
higher at day 2 post-treatment compared to day 5 post-treatment. The DTG levels in liver at day 2 
and day 5 were 112±42 ng/g (IV) and 91.2±32 (IM) ng/g versus 47.3±44 ng/g (IV) and 27.12±15 
ng/g (IM), respectively; whereas, DTG levels in the spleen at day 2 and day 5 were 39.3±21 ng/g 
(IV) and 82.4±41 ng/g (IM) versus 54.8±23.3 ng/g (IV) and 15.12±5.4 ng/g (IM), respectively. In 
general, both IV or IM administration of nanoparticles showed coordinate tissue and plasma drug 
and cobalt levels. Liver macrophage uptake of nanoparticles was 2.5-fold higher than splenic 
uptake of nanoparticles (Figure 3.5A-C). A correlation analysis of iron levels obtained by MRI, 
cobalt levels by ICP-MS, and DTG drug levels by UPLC-MS/MS was performed in both the liver 
and spleen in IV and IM injected animals to validate the usefulness of MRI to track nanoparticles 
in real-time. Figure 3.5F shows Pearson correlation plots between in vivo MRI iron levels and both 
tissue DTG and cobalt concentrations. Day 5 iron levels measured by MRI are plotted versus cobalt 




a strong correlation between iron, cobalt, and DTG concentrations within the liver and spleen, with 
Pearson’s correlation coefficients of r = 0.8949 within the liver, r = 0.9396 within the spleen, r = 
0.6505 within both liver and spleen for iron versus cobalt, and r = 0.789 within both liver and spleen 
for iron versus drug. DTG and iron levels within the liver and spleen were directly related to cobalt 
concentrations as measured by ICP-MS (Figure 3.5D). Such data suggests that MRI can be used to 
estimate the amount of drug that accumulates within reticuloendothelial tissues by using the known 
in vivo MRI signal-to-drug ratio for EuCF-DTG nanoparticles (Figure 3.7)  
Investigation of the biodistribution of EuCF-DTG nanoparticles by MRI in rhesus 
macaques was performed to confirm whether the data sets observed in the in vivo rat biodistribution 
studies could possibly be observed in a species that is much more closely related to humans. Plasma 
and tissue DTG and cobalt concentrations were also measured ex vivo. The liver and kidneys of the 
rhesus macaques displayed the highest concentrations of cobalt and DTG, with detectable levels 
also being observed in the spleen and lymph nodes (Figure 3.8) Very small amounts of drug or 
cobalt was detected within the lungs. Such data suggests that macrophages within 
reticuloendothelial tissues of macrophages take up EuCF-DTG nanoparticles.  
3.3.3 Intracellular macrophage nanoparticle trafficking in rat tissues  
Immunohistology and TEM was performed ex vivo on rat tissues to confirm the localization 
of nanoparticles within the liver and splenic macrophages. Figure 3.9A shows tissue sections of 
liver and spleen from animals sacrificed 5 days post-EuCF-DTG injection (IM and IV). Tissues 
were probed with Iba-1 antibody to identify activated macrophages. The yellow/orange color 
highlighted by arrows within the merged images is indicative of the co-localization of EuCF-DTG 
nanoparticles (green) within the activated macrophages (red).  Figure 3.9B shows corresponding 
TEM images of liver and spleen sections 5-days post injection of EuCF-DTG nanoparticles. Blacks 
dots can be clearly seen within TEM images in both IV- and IM-injected animals and represent the 




the spleen. Such immunohistological and TEM data are in strong agreement with in vitro results 
listed in the previous chapter and suggests that nanoparticle retention within these tissues persists 
for at least 5 days. Parallel immunohistochemistry studies were performed in rhesus macaque 
tissues 5-days post IM injection of EuCF-DTG nanoparticles; histological evaluation was 
conducted in accordance with the guidelines of the Society of Toxicologic Pathology, and no 
anomalies were found other than those that are common in SIV infected animals.  Biochemical or 
hematological effects of EuCF-DTG nanoparticle administration to rhesus macaques were not 
observed. 
3.4 Discussion  
Synthesized theranostic nanoparticles contain individual functional components that 
improve their diagnostic and therapeutic potential. First, the CF component enhances MRI signal 
sensitivity and specificity measures [223]. The images show excellent T2 relaxivity. As such, they 
can be readily used for ARV biodistribution studies. High relaxivity results in enhanced sensitivity 
for ferrite quantification. Second, the nanoparticle’s unique spinel structure permits the 
incorporation, in a formed lattice, of rare earth elements. This includes, but is not limited to, 
neodymium, Eu3+ and gadolinium [223, 242]. Third, Eu3+ provides magnetic and fluorescence 
capabilities. Fourth, the translational potential is realized through the nanoparticle’s 
biocompatibility [223]. This is facilitated through the outer “soft” lipid layer of the EuCF-DTG 
nanoparticles [214, 243]. Fifth, Eu3+ doped CF can be surface-modified by FA for functionalization 
[223]. Sixth, the formed FA-EuCF-DTG nanoparticles are highly stable and as such can be made 
for systemic use. Seventh, the FA-EuCF-DTG nanoparticles are hydrophilic with a narrow size 
distribution. Each contains a “hard” inner matrix of an organic-inorganic hybrid of EuCF and PCL, 
which enables the nanoparticles to be loaded with hydrophobic ARVs and have limited to no 
toxicities [214]. Eighth, the nanoparticles unique physicochemical properties facilitate entry into 




with PC, DSPE-PEG2000 and DOPE. The lipid surrounding the EuCF-DTG core serves to 
facilitate rapid uptake by macrophages and as such effectively distribute drug into tissue viral 
reservoirs. Ninth, the lipid layer shell over the nanoparticle’s core provides inherent stability and 
appropriately sized nanoparticles can be readily made in order to optimize cell and tissue delivery. 
Indeed, the EuCF-DTG and FA-EuCF-DTG nanoparticles are homogeneous with relatively narrow 
nanoparticle size distribution and retention of drug loading capacities and antiretroviral activity. 
Tenth, the nanoparticle’s size and shape are comparable to that of LASER ART being developed 
for clinical use [202, 229]. The nanoparticles are remarkably consistent in morphology. Electron 
microscopic images indicate that all synthesized nanoparticles display lipid layers outside the 
EuCF-DTG or FA-EuCF-DTG core matrix. The latter appears smooth with uniform topography 
that is particularly important in reducing systemic adverse events. Eleventh, the uptake of 
nanoparticles by macrophages is optimized, as endocytosis is facilitated by spherical or semi-rod-
shaped nanoparticles [206, 244-246]. 
Prior reports demonstrated that the FA receptor beta (FR-β), highly expressed on 
macrophages, could facilitate nanoparticle cell entry [216, 217, 220]. We have previously 
demonstrated significantly higher macrophage uptake of FA-decorated nanoformulations 
compared to replicate nanoformulations without decoration [206, 247]. In particular, ARV 
nanoparticles that were decorated with FA showed higher atazanavir levels in lymphoid organs 
such as the spleen and lymph nodes compared to non-decorated particles. Notably, drug levels 
paralleled FR-β staining in both macrophage-rich parafollicular areas of spleen and lymph nodes. 
FA targeting of abacavir nanoparticles improved drug and pharmacokinetics and antiretroviral 
activity [196]. Moreover, demonstration of human serum albumin nanocapsules that were surface 
modified with FA led to macrophage internalization [218]. Formulation uptake was three-fold 
higher in FR-β-positive macrophages than in macrophages not expressing FR-β. Similarly, FR-β-




collagen-induced arthritis models [219]. Furthermore, macrophage targeting of FA-conjugated iron 
oxide nanoparticles were described [215] and reflect our own results. In the current report, we 
showed higher uptake of FA-EuCF DTG nanoparticles in reticuloendothelial tissues (Figure 3.4, 
Figure 3.6). Moreover, we confirmed that FA decorated nanoparticles showed higher macrophage 
uptake (Figure 3.4) [206, 247]. Therefore, the macrophage-targeting strategy presented in our study 
for FA-mediated uptake of nanoparticles will enable targeting of nanoformulated drug particles. 
Nanoparticle migratory behavior was investigated in rodents and non-human primates. MR 
images showed decreased signal intensity within the liver and spleen. Corresponding MRI T2 
values revealed that iron levels matched the drug PK and biodistribution profiles. Validations were 
made by analysis of cobalt and drug content. No significant differences in deviation from linearity 
for either drug or cobalt levels were found over time. Co-localization of nanoparticles within 
macrophages was seen using confocal and electron microscopy in both cell culture and 
histopathological tissue analyses, highlighting the importance of Eu3+ as a fluorescent tag. Assay 
of cobalt and iron along with drug content provided MRI confirmation results. Our finding of 
preferential macrophage uptake of nanoparticles paralleled the observed PK and biodistribution 
results [243-246]. With the successful development of the multi-modal nanoprobes in rhesus 
macaques, we posit that macrophage-targeted theranostics can be useful as a testing platform to 
assess drug biodistribution in humans. Macrophages loaded with theranostic nanoparticles can 
move throughout the body and target tissue sites of residual latent virus [207, 248, 249]. Notably, 
the nanoparticles maintain their integrity and ARV efficacy. Most importantly, nanoparticle 
distribution can be monitored and tracked in real-time [207, 223]. Overall, our newly-developed 
platform provides a means to accurately and effectively optimize the delivery of antiretroviral drug-





In conclusion, the efficacy and structural integrity of the nanoprobe platform was 
confirmed in rats and SIV-infected rhesus macaques by MRI. FA-functionalized EuCF-DTG 
nanoparticles showed enhanced nanoparticle uptake and antiretroviral activity. EuCF-DTG was 



























Figure 3.1 MRI relaxometry measurements (c-d) MRI signal enhancement effects of EuCF-
DTG and FA-EuCF-DTG nanoparticles were determined by calculating nanoparticle relaxivity r2 
(mM−1s−1) in both PBS (extracellular) and MDM (intracellular) using a 7T MRI scanner. (C) 
Nanoparticle relaxation rates (R2) in both PBS and MDM increased linearly with increasing iron 
concentrations. (D) T2-weighted images of EuCF-DTG nanoparticles in PBS demonstrate signal 
























Figure 3.2 Nanoparticle biodistribution tests. (A) Time line of the experimental procedure in 
the rats is shown (NP: nanoparticles). (B) Representative T2 maps of rats at 2, 5 and 10 days after 
IV or IM administration of 2 mg iron/kg as EuCF-DTG nanoparticles (yellow: lung; red: liver; 

















Figure 3.3. (C) Schematic diagram of macrophage-based biodistribution of EuCF-DTG 
nanoparticles in the reticuloendothelial system of rhesus macaques (IM: intramuscular). (D) 
Representative T2-weighted images of a macaque at 5 days after IM administration of 2 mg iron/kg 









































Figure 3.4: FA-EuCF-DTG nanoparticle biodistribution: (A) Schematic diagram of 
macrophage-based biodistribution of particles in rats reticuloendothelial system (IV: intra 
intravenous). Nanoparticles were administrated in Male Sprague Dawley rats followed by IV or IM 
injection and underwent MRI scanning immediately before injection as well as 2 and 5 days post-
injection. (B) MR images of rats at day 5 after IM/IV administration of 2 mg iron/kg FA-EuCF-
DTG particles (yellow: lung; red: liver; green: spleen). (C) MRI T2 mapping again quantified the 
iron concentrations in the liver and spleen. Statistical differences were determined using one-way 


















Figure 3.5: Biodistribution of FA-EuCF-DTG nanoparticles in rats. (A) Iron level comparisons 
for EuCF-DTG and FA-EuCF-DTG nanoparticle in liver and spleen measured by MRI. (B) Cobalt 
concentrations within lymphoid tissues and (C) brain, kidney and lung cobalt levels measured by 
ICPMS. (D) Plasma cobalt and (E) DTG concentrations were measured after IV or IM 
administration for EuCF-DTG nanoparticles. (F) Pearson’s correlation in liver and spleen tissues 
of cobalt levels (determined by ICPMS) in tissues as compared to iron levels determined by MRI 
five days after injection of EuCF-DTG nanoparticles (2 mg iron/kg). Statistical differences were 




















Figure 3.6 Drug and cobalt concentrations after parenteral EuCF-DTG administration. 
Sprague Dawley rats were administered EuCF-DTG nanoparticles (2 mg/kg iron content) by IM or 
IV injection on day 0 and sacrificed on days 2, 5 or 10. Plasma was collected for drug analysis on 
days 1, 2, 5, and 10 after treatment. DTG and cobalt levels were determined by UPLC-MS/MS and 
ICP-MS, respectively, at days 2, 5 and 10. (A) Quantitation of iron in liver and spleen by MRI tests. 
(B) Cobalt concentrations. (C) Tissue DTG concentrations. (D) Pearson’s correlation of iron 
(determined MRI), cobalt (determined ICP-MS) and DTG (determined UPLC-MS/MS) 
concentrations in liver and spleen tissues five days after IV/IM administration of nanoparticles. 
Statistical differences were determined using two-way ANOVA among groups; ***p < 0.001; 















Figure 3.7 Prediction correlations of cobalt and DTG levels in tissues (DTG data sets were 
obtained from an independent publication [12]). Cobalt and DTG levels in the tissues were analyzed 
by ICP-MS and UPLC-MS/MS. No significant differences in deviation from linearity for either 
function (p = 0.6667 and p = 1.0000) were observed. In addition, no significant differences were 
observed in the rate of change, by slope measures, in either DTG or cobalt concentrations (p = 
0.476). Noted differences in line elevation (p = 0.0011) were linked to the relative concentrations 













Figure 3.8: Biodistribution of EuCF-DTG nanoparticles in rhesus macaque tissues and effect 
on simian immunodeficiency virus (SIV) RNA loads. (A-C) plasma (results are shown as means 
± SEM; n=3) and tissue viral RNA loads of SIV-infected rhesus macaque. (D) Rat and rhesus 
macaque T2 relaxation in liver, (E-F) effect of EuCF-DTG treatment on plasma and comparison of 
DTG concentrations in post-mortem tissues measured by ICP-MS 5 days post IM injection of 
EuCF-DTG nanoparticles and (G-H) cobalt concentrations in the reticuloendothelial organs and 

























Figure 3.9 Immunohistochemical and morphological localization of EuCF-DTG 
nanoparticles. (A) Representative tissue sections of liver and spleen of rats administered EuCF-
DTG nanoparticles (green) were stained for Iba-1 (red) on activated macrophages. Nanoparticles 
were detected in macrophages in both liver and spleen. Arrows in the merged figures indicate co-
localization of nanoparticles in macrophages. Images were captured with 63X objective on a Zeiss 
LSM 710 confocal microscope. (B) TEM of liver and spleen 5 days after IV or IM injection of 
EuCF-DTG nanoparticles (2 mg iron/kg). Panels ii and iii are higher-powered images from regions 
indicated by red arrowheads in panel i. Presence of nanoparticles (black dots) is seen in 
macrophages in both liver and spleen (panel ii and iii, Figure S11. FA-EuCF-DTG nanoparticles 










Nanoformulated antiretroviral therapy attenuates brain 




























4.1 Introduction  
HIV-1 infection is associated with a spectrum of comorbid conditions that includes the 
CNS [250-252]. Nonetheless, many of these conditions have been either reduced or eliminated 
following the widespread use of ART. ART has enabled infected people to live nearly normal lives 
by reducing plasma and tissue HIV-1 RNA to levels below the limits of detection [7, 174]. 
Nonetheless, disease morbidities remain, albeit at lower levels, both as a consequence of viral 
infection and concomitant illnesses. This includes abuse of illicit drugs, nutritional deficiencies, 
neuropsychiatric disorders, and a variety of comorbid infectious diseases that include hepatitis and 
opportunistic viral and parasitic infections. Malignancies, depression, and immune dysfunctions 
are specifically linked to cognitive and behavioral abnormalities as areARVs themselves. The latter 
plays a role in direct neurotoxicity and consequent neuropsychiatric compromise [253, 254]. 
Among them, to date, efavirenz is known to affect neuronal function [255]. The potential effects 
that other ARVs may have on brain function and metabolism remain poorly understood. Such drug-
associated toxicities could become more pronounced as commonly used ARVs are transformed 
into LASER ART. Such achievements have been made possible by chemical drug modifications 
enabling lipophilic hydrophobic nanocrystals to be created that markedly prolong the drug’s 
apparent half-life [256, 257]. One of the ARVs, dolutegravir (DTG), has received notable attention 
for its potential for transformation into a long-acting drug as well as its potential albeit rare 
toxicities [256]. In 2013, DTG was approved by the U.S. Food and Drug Administration and soon 
afterwards broadly incorporated in combination ART regimens based on its potency and limited 
viral resistance patterns [258-260]. While the drug is generally well tolerated, reports have emerged 
that in some aged patients and females, adverse events could signal off-target drug effects involving 
the CNS [256]. Given DTG’s key role in HIV-1 therapeutic regimens, studying the intricate 
metabolic mechanism of how and why neural effects occur could improve disease outcomes. 




any means to prevent it appears timely. The realization of LASER ART could, in part, facilitate 
any untoward drug effects as the circulating drug half-life broadens further. Alternatively, 
nanoformulated drug improvements in ARV uptake, retention, and biodistribution into tissues and 
organs where free drug may not easily reach could attenuate adverse events by further reducing the 
impact of virus on disease events and in control of untoward macrophage inflammatory responses. 
Indeed, while LASER ART can significantly improve antiretroviral clinical potency, it requires 
high doses to maintain the required four times the effective dose 90 in plasma to elicit sustained 
viral restriction [257, 261-266]. With this in mind, we investigated the metabolic effects of free and 
nanoformulated DTG in five different anatomical brain regions using untargeted and unbiased 
metabolomic detections. DTG was administered intramuscularly at 45-mg/kg doses over a 7-day 
time course. This enables up to 100 times the oral therapeutic plasma concentration. Reported 
steady-state plasma concentration obtained from HIV-1-infected adults after ten doses of 
monotherapy with 50 mg (once daily) DTG tablets is 3.34 μg/mL (Cmax), whereas in the current 
study, plasma concentration of injectable DTG for a single free DTG injection was up to 11.29 
μg/mL [267, 268]. The frontal cortex (FC), ventral cortex (VC), dorsal cortex (DC), hippocampus 
(H), and cerebellum (CR) were dissected and then analyzed using liquid chromatography-mass 
spectrometry (LC-MS)- based global metabolomics. The results showed that “high parenteral 
doses” of free DTG induced disordered brain metabolism as defined by increases in specific 
energy-related metabolites and their pathways all linked to oxidative cellular processes. These were 
seen predominantly in the cerebellum and cortex and were attenuated to basal levels by the use of 
DTG delivered as a nanoformulation. While higher dosages of DTG could affect neurotoxicities, 
any concern in such administration as a long-acting antiretroviral was abrogated by an established 
nanoformulated drug delivery system. 
4.2 Materials and methods  




For preparation of P407-DTG, 0.5% (w/v) P407 was mixed with 1% drug. The suspensions 
were homogenized at 20,000 psi using an Avestin Emulsiflex C3 homogenizer (Avestin Inc., 
Ottawa, ON, Canada) until the desired particle size (300– 400 nm) was reached. Free polymers and 
nonencapsulated drug particles were removed by centrifugation; the nanoparticles were 
resuspended in 0.2% P407. Drug loading was determined using reversed-phase high-performance 
liquid chromatography (HPLC) and ultra-performance liquid chromatography tandem mass 
spectrometry (UPLC-MS/MS) as described. Particle size, polydispersity, and zeta potential for the 
nanoformulations were determined by dynamic light scattering using a Malvern Zetasizer Nano-
ZS instrument (Malvern Instruments Inc., Westborough, MA, USA). 
4.2.2 DTG injection and brain tissue collection  
Both nanoformulated and free DTG with their corresponding controls (vehicle only) were 
introduced by intramuscular injections with a loading dose of 45 mg/kg. Animals treated with 
nanoformulations were treated once while the free DTG group was treated every other day over a 
1-week span (i.e., 4 total injections over 7 days) to maintain drug levels in the animals. Free DTG 
was dissolved in a buffer of (v/v) 43% ethanol, 5% cremophor, 20% propylene glycol (propane-
1,2-diol), and 32% PBS. In the global metabolomics analysis, the same buffer and nanoformulation 
without DTG were used as controls. Mice were anesthetized with 1–2% isoflurane in oxygen and 
then aligned in a water-jacketed holder for microwave irradiation with a Muromachi Microwave 
Fixation System (10-kW model, Muromachi Kikai Co., Ltd., Chuo-ku, Tokyo, Japan). Irradiation 
time was 800 ms at 4.9 kW [269]. Single voxel localized spectra were acquired post-mortem at the 
midbrain to ensure metabolite level stabilization using point-resolved spectroscopy. Spectra were 
acquired with a repetition time of 4 s and echo time of 50 ms, 128 averages, using birdcage coil 
transmit, and received on a 7-Tesla/16-cm Bruker Pharmascan (Karlsure, Germany) MRI/MRS 
system. Single-scan, localized, unsuppressed water signals were acquired as a reference for 




were eliminated from further analysis. Five animals were selected for further brain dissection and 
analysis. All specimens were from the same genetic strain (Balb/cJ), males and similar ages (7 
weeks). After spectroscopic validation of microwave irradiation euthanasia, brains were isolated 
and initially split into hemispheres, with both hemispheres dissected into subregions. Subregional 
dissection followed anatomical boundaries to separate the frontal cortex, ventral cortex, dorsal 
cortex, hippocampus, and cerebellum. Following dissection, all tissues were flash frozen in dry ice 
and stored at − 80 °C. 
4.2.3 Metabolome extraction  
Brain tissue subregions were extracted as previously described [270]. Briefly, 0.6 mL of 
cold methanol:H2O (4:1, v/v) were added per 10 mg tissue (solvent volume was adjusted 
accordingly to tissue weight). Homogenization was performed with glass beads in a homogenizer 
and sonicated in an ice bath for 10 min. The mixtures were then transferred to 1.5-mL Eppendorf 
vials and rinsed with additional 200 μL extraction solvent. To precipitate proteins, the samples were 
incubated for 1 h at − 20 °C, followed by a 15-min centrifugation at 13,000 rpm at 4 °C. The 
resulting supernatant was evaporated to dryness in a vacuum concentrator. The dry extracts were 
then reconstituted in acetonitrile:H2O (1:1, v/v), normalized by tissue weight, sonicated for 10 min, 
and centrifuged for 15 min at 13000 rpm and 4 °C to remove insoluble debris. The supernatants 
were transferred to HPLC vials and stored at − 80 °C prior to LC-MS analysis. 
4.2.4 HILIC-MS and data analysis  
The extracts were analyzed on a 6550 iFunnel QTOF mass spectrometer coupled with a 
1290 UPLC system (Agilent Technologies, Santa Clara, CA). For global metabolomics, a Luna 
Aminopropyl, 3 μm, 150 mm × 2.0 mm I.D. HILIC column (Phenomenex, Torrance, CA) was used. 
The mobile phase was composed of A = 20 mM ammonium acetate and 40 mM ammonium 




A (17–33 min) was applied with a 15-min re-equilibration time. The flow rate and injection volume 
were 250 μL/min and 5μL, respectively .ESI source condition swere set as follows: dry gas 
temperature, 200 °C; flow, 11 L/min, fragmentor, 380 V; sheath gas temperature, 300 °C; flow, 9 
L/min; nozzle voltage, 500 V; and capillary voltage,− 500 Vin ESI-negative mode. The instrument 
was set to acquire data over the m/z range 50–1000, with the MS acquisition rate of 1 spectra/s. 
The sample sequence was randomized to avoid systematic decreases in signals over sample sets. 
For the MS/MS of selected precursors, the default isolation width was set as narrow (∼ 1.3 m/z), 
with a MS acquisition rate at 2 spectra/s and MS/MS acquisition at 2 spectra/s to acquire over the 
m/z range 50–1000 and 25–1000; respectively. MS/MS data were acquired at the collision energy 
of 20 V. LC-MS data were converted to mzXML files using Masshunter Acquisition Software 
(Agilent Masshunter 6.0B). The mzXML files were uploaded to XCMS Online web platform for 
data processing (https://xcmsonline.scripps. edu) including peak detection, retention time 
correction, profile alignment, and isotope annotation [271]. Data were processed using both 
pairwise and multigroup comparisons, and the parameter settings were as follows: centWave for 
feature detection (Δ m/z = 15 ppm, minimum peak width = 10 s, and maximum peak width = 60 
s); obiwarp settings for retention time correction (profStep = 0.5); and parameters for 
chromatogram alignment, including mzwid = 0.015, minfrac = 0.5, and bw = 5. The relative 
quantification of metabolite features was based on extracted ion chromatogram areas. Paired 
parametric t test and one-way ANOVA (post hoc Tukey test) were used to test the variation pattern 
of metabolite features between and across cell samples. The result outputs, including EICs, 
pairwise/multigroup cloud plot, multidimensional scaling plots, and principle components, were 
exported directly from XCMS Online. Generally, the numbers of total pairwise comparison features 
and significantly altered features (statistically defined as p value < 0.01, including both upregulated 
and downregulated features) were reported in this study. 




Human monocyte-derived macrophages (MDM) were isolated and then differentiated as 
described [227]. MDM were cultured in Dulbeccos Modified Eagle medium (Invitrogen) 
supplemented with 2 mM L-glutamine, 100 μg mL−1 streptomycin, 100 U mL−1 penicillin, and 
2% fetal calf serum. Murine neurons were isolated from E16-E17 (embryonic) mouse whole brain 
tissues. Briefly, embryonic day 16 mice were harvested by cesarean section from anesthetized 
pregnant dams (C57BL/6 strain). The animal protocol was approved by the Animal Care and Use 
Committee of University of Nebraska Medical Center. Whole brain tissues were isolated and 
dissociated by 10% (v/v) trypsin (Life Technologies, Bethesda, MD) digestion and trituration with 
a fire-polished Pasteur pipette. Cell culture dishes were coated with 33 μg/mL poly-D-lysine. The 
cells were plated in neurobasal medium supplemented with B27, 300 μM glutamine, 25 μM 
mercaptoethanol, and streptomycin/amphotericin B (Life Technologies, Waltham, MA). Three 
days after plating, 50% of the medium was changed and subsequently the medium was changed 
every 6 days. Cells were maintained in the culture for 8–10 days for complete differentiation before 
any treatment. 
4.2.6 Cell-based DTG measurements  
MDM and neuron cells with different treatments were rinsed with phosphate-buffered 
saline (PBS) and extracted with acetonitrile:H2O:methanol (2:1:2, v/v/v) using freeze-thaw method 
as described elsewhere [270]. The samples were centrifuged at 16,000g at 4 °C for 15 min and the 
supernatant was directly injected into the triple-quad 6495 (Agilent Technologies, Santa Clara, CA) 
operated in multiple reaction monitoring mode (MRM), where the collision energies and product 
ions (MS2 or quantifier and qualifier ion transitions) were pre-optimized (quantifier ion 420 to 295 
and qualifier ion 420–277). Cycle time was 150 ms for each transition. ESI source conditions were 
set as following: gas temperature 250 °C, gas flow 14 L/min, nebulizer 20 psi, sheath gas 250 °C, 
sheath gas flow 11 L/min, capillary voltage 3000 V, nozzle voltage 1500 V, and EMV 1000 V in 




mm, 1.7 μm) (Waters Corporation, Milford. MA). The mobile phase was composed of A = water 
with 20 mM ammonium formate and 0.1% formic acid and B = acetonitrile with 0.1% formic acid. 
A linear gradient from 5% B (0–0.5 min) to 30% B (0.5– 5 min, maintaining for 2 min) was applied. 
Then, the gradient was set to the initial 5% B within the next 1 min. A 2-min reequilibration time 
was applied to the column for re-equilibration. The flow rate was 200 μL/min, and the sample 
injection volume was 2 μL. 
4.2. 7 Reactive oxygen species (ROS) measurements  
ROS were measured in neuron and MDM cells with the probe DCFDA (dichlorofluorescin 
diacetate, abcam, Cambridge, MA). Cells were seeded on black, clear-bottomed 96-well plates. 
After cells were pre-cultured with different treatments, the media were removed and the cells were 
washed with 1 × buffer (supplied with the kit). Cells were incubated for 45 min in 1× buffer 
containing 25 μM DCFDA at 37 °C. DCF production was measured by fluorescence spectroscopy 
with excitation wavelength at 485 nm and emission wavelength at 535 nm. In this study, the cells 
were treated with increasing concentrations of free DTG, nano-DTG, and various vehicle, positive, 
and negative controls to compare ROS generation and lactate dehydrogenase (LDH)-based 
cytotoxicity generated by such treatments. The highest DTG levels measured in the mouse brain is 
in the micromolar range so the highest dosing concentration used for ROS experiment was set to 
500 μM in the dosing medium, which did not show significant cytotoxicity. TBHP (tert-butyl 
hydroperoxide; 10 μM) and PBS were used as the positive and negative controls, respectively. The 
vehicle control for nanoformulated DTG was composed of poloxamer micelles without the drug. 
The vehicle control for free DTG was composed of 43% ethanol, 5% cremophor, 20% propylene 
glycol (propane-1,2-diol), and 32% PBS (v/v). To further validate the protective effect of the P407 
nanoformulation in mediating the oxidative stress, we conducted additional experiments to measure 
ROS formation in neurons and MDM cells treated with free and nanoformulated DTG with a series 




to induce further oxidative stress. Specifically, cells (both MDM and neurons) were treated for 2 h 
with various vehicle or drug concentrations. Then, cells were washed and new media was added, 
and after 24-h culture, cells were challenged with TBHP for 2 h, followed by fluorescence-based 
ROS measurements. 
4.3 Results 
4.3.1 Brain region-specific metabolomics after free and nanoformulated DTG injections 
Following free and nanoformulated DTG mouse injections, global metabolomics were 
performed on five dissected brain subregions including the FC, VC, DC, H, and CR (Figure 4.1). 
The effects of free DTG on the brain metabolome were more pronounced within the FC and CR 
(Figure 4.2a). In free DTG treated mice, the FC and CR showed the most pronounced metabolite 
dysregulations with 130 and 73 features in comparison to 50, 58, and 61 for the VC, DC, and H. 
Each of the numbers listed are posted in comparison to controls. The dysregulated metabolites 
observed in the CR overlapped, in part, with those observed in the other four brain subregions. In 
contrast to the metabolite effects seen by free DTG, nanoformulated DTG-treated animals showed 
few dysregulated features. Interestingly, the number of dysregulated features had a narrower range 
from 33 to 17, which on average represents a third of the number in the free DTG treatment group. 
Furthermore, equivalent DTG drug concentrations were measured in all five brain regions in mice 
treated with either free or nanoformulated DTG, demonstrating the advantages of increased 
macrophage uptake and retention and apparent plasma drug half-life of the nanoparticle delivered 
DTG compared to free drug as a delivery system. Statistical significant differences in DTG 
concentrations were only observed in the H, where lower drug concentrations were measured in 
the nanoformulated drug-treated mice. However, the fold change (0.63) was valued as small and 
unlikely to affect the observed metabolite response differences (Figure 4.2b). Indeed, DTG 
nanoparticles are rapidly endocytosed by macrophages and release drug in a controlled manner in 




Among the many dysregulated metabolites seen in brain subregions in the free DTG-
treated group, the most affected were identified as energy-related pathways, including glycolysis 
and the tricarboxylic acid (TCA) cycle (Figure  4.3). Also, the dysregulation of nicotinamide 
adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), known 
cofactors in redox reactions, proved highly relevant due to linkages to oxidative stress related to 
xenobiotics and environmental pollutants affecting biological systems. The dysregulation of these 
was not observed between controls and DTG nanoparticles, which suggests negligible drug brain 
metabolic disruption when DTG was encased in nanoformulations. 
4.3.2 DTG and oxidative stress  
In addition to energy-related pathways, the most significant change in DTG-induced brain 
metabolism was in ascorbic acid and glutathione degradation. These changes are depicted in Figure. 
4.4 for both free (a, b) and nanoformulated (c, d) DTG in each brain subregion. These values 
represent the ratio of the amount found in the controls divided by the amount found in the treated 
mice for ascorbic acid and GSH, as they are depleted with oxidative stress. Conversely, the values 
for threonate and GSSG represent the ratio of the amount found in the treated mice divided by the 
amount found in their corresponding controls. In these assays, higher ratios reflect greater degrees 
of oxidative stress seen as visual darker shades with oxidation, red for depletion of protecting 
metabolites (ascorbic acid and GSH) and green for the increase in oxidation 
products (threonate and GSSG). 
The most substantial changes in ascorbic acid levels were observed in the FC and CR in 
animals treated with free DTG. Similarly, increases in threonate further support the presence of 
oxidative stress (Figure. 4.4a). Analogous to ascorbic acid and threonate metabolic dysregulation 
in free DTG treatment groups, GSH and GSSG showed similar effects with the exception of 
increases in oxidative stress seen across each of the five brain regions (Figure. 4.4b). All changes 




acid levels observed in the H (Figure 4.6). In contrast to free DTG, nanoformulated DTG treated 
animals showed less ROS brain-associated metabolic dysregulation. In Figure. 4.4c, d, more limited 
changes were seen without statistical significance compared to controls. It should be noted that 
similar brain drug levels between free and nanoformulated drugs were seen across both 
formulations and as such cannot explain the experimental differences (Figure 4.2b). To investigate 
the metabolic source of the oxidative stress and the association with nanoformulation, a number of 
mechanistic laboratory experiments were performed for cross validation and extension. 
4.3.3 Nanoparticle DTG encasement abrogates brain oxidative stress 
In attempts to elucidate any neuroprotective mechanism underlying the DTG 
nanoformulations, we employed mouse embryonic neuron cells and human MDM for testing. Each 
was treated with free and nanoformulated DTG with the addition of their respective vehicle 
controls. ROS formation was measured orthogonally in neurons and MDM using fluorescence 
based commercial kits (DCFDA, Figure 4.5a, b, respectively) and administered at 100 and 500 μM. 
Values are reported as fold changes compared to respective vehicle controls. Neurons treated with 
free but not nanoformulated DTG showed increases in ROS of up to 1.5 times of control. In contrast 
for MDM, free and nanoformulated DTG induced more limited ROS effects altering metabolite 
concentrations 0.8 and 1.2 times, respectively, when given at 100 μM. The abilities of nanoparticles 
to modestly increase ROS suggested that P407 by itself is not an antioxidant but that the protective 
mechanism could be more physically linked. ROS levels in free DTG cell cultures were higher than 
those in the vehicle controls as aligned with the notion that DTG can itself induce oxidative stress. 
More interestingly, comparisons between free and nanoformulated DTG supported the hypothesis 
that nanoformulation can reduce oxidative stress and protect neurons (Figure 4.7a–d). In attempts 
to sort out these differences and to better elucidate the effects of free and nanoformulated DTG and 
relevant drug delivery vehicles on ROS induction, we performed dose-response ROS induction 




treated with both free and nanoformulated DTG (concentration between 10 and 100 μM) followed 
by the addition of 10 μM TBHP as an oxidative stress inducer. As shown in Fig. 5c, a clear ROS 
response was seen in neurons treated with either free or nanoformulated DTG, while no effect was 
seen for vehicle controls. Most importantly, for MDM (Figure. 4.5d), free DTG challenged with 
TBHP induced ROS formation in a dose-response at higher concentrations (60 to 100 μM), 
reflective of what was observed previously in neurons. In contrast, addition of nanoformulated 
DTG to the cultures attenuated the TBHP response signaling control of ROS or the ability to buffer 
such effects by the nanoformulations. These latter data provide a mechanism for how the 
nanoformulation could control ROS production in specific brain regions. Finally, we measured 
cellular uptake of free and nanoformulated DTG at 1, 10, and 100 μM (Figure 4.5e, f) in attempts 
to better uncover mechanisms. As shown in Figure 4.5e, the concentrations of nanoformulated DTG 
in neurons were almost one order of magnitude higher than those in the free DTG drug. However, 
for MDM, the concentration was similar between two forms of DTG treatment (Figure 4. 5f), which 
could be explained by different drug uptake mechanisms, biotransformations, and cell metabolic 
capacity between both cell types. However, considering the fact that DTG concentrations of nano-
DTG-treated cells are one order of magnitude higher than those of free DTG-treated cells at the 
same dosing concentration (Figure 4. 5a, b), the nanoformulations shows its protective effect in 
modulating ROS level (e.g., fold change of 4 at 100 μM for free DTG and fold change of 1.2 at 10 
μM for nano-DTG). As for MDM cells (Fig. 4.5f), the free DTG drug challenged with TBHP 
induced ROS formation with a clear concentration-response at higher concentrations (60 to 100 
μM), similar to neurons. This explains, in part, the unexpected increase in ROS production during 
initial TBHP challenge in neurons (Figure 4.5c). 
4.4 Discussion  
The possible link between ART and neurotoxicities has only been postulated. Here, we 




free and nanoformulated drugs. The results showed that while free DTG delivered at high doses 
can affect the brain metabolism for oxidative stress, the effects can be curtailed by how the drug is 
formulated. Altogether, our results affirm that if and when DTG is used in part of a LASER ART 
regimen, it can be administered safely. It is acknowledged and despite restricted viral growth by 
cART, up to 60% of HIV-1- infected patients show HAND-related cognitive and behavioral 
abnormalities induced by comorbid infectious, cancerous, metabolic, and neuropsychiatric events 
[175]. ARVs themselves are potential contributors and most can elicit varying degrees of 
neurotoxic reactions. Each of these “purported” adverse effects is independent of drug class that 
includes nucleoside reverse transcriptase inhibitors (NRTIs, e.g., abacavir and lamivudine), non-
NRTIs (e.g., efavirenz), entry inhibitors (e.g., maraviroc), inhibitors of the viral protease (e.g., 
atazanavir), and integrase inhibitors (INSTI, e.g., DTG). Notwithstanding, each of the drugs has 
revolutionized patient care and has improved longevity and disease morbidities considerably, and 
to the degree, HIV-1/AIDS is now a treatable chronic, managed disease. DTG, in particular, is used 
commonly in both first- and second-line therapies that have been projected by 2019 to account for 
37% of the adult first-line NNRTI/INSTI market, representing 3.8 million patients [272]. Compared 
to NRTIs, DTG is durable and can cross the BBB allowing it to easily achieve therapeutic brain 
concentrations [273]. However, side effects of DTG are reported and include insomnia and 
headache as well as more significant allergic reactions and abnormal liver function in dual hepatitis 
virus-infected people [259]. Low concentrations of DTG can trigger suicidal death in erythrocytes 
characterized by cell shrinkage and membrane scrambling with phosphatidylserine translocation to 
the erythrocyte surface [274]. Putative neuropsychiatric effects were reported in adult patients who 
received DTG, raltegravir, and elvitegravir, suggesting specific toxicities linked to integrase strand 
transfer inhibitors [253, 256, 275-279]. Nonetheless, others have debunked such results with a sole 
substantiated DTG metabolic effect being a rise in serum creatinine due to tubular secretion 




Oxidative stress plays a principal role in the pathogenesis of neurodegenerative disorders 
including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and HIV-1 
associated dementia [282]. A spectrum of xenobiotics, mitochondrial dysfunction, accumulation of 
aberrant misfolded proteins, inflammation, and defects in protein clearance are all known to 
accumulate ROS. Xenobiotics can be oxidized to free radicals by cytochrome P450 and generate 
ROS following the quenching of the radicals. DTG has been shown to be oxidized by CYP3A4, 
even though the major metabolic reaction was glucuronidation of DTG principally by metabolic 
reaction was glucuronidation of DTG principally (in humans) [283]. Dysregulation of glycolysis, 
TCA cycle, and redox cofactors could indicate a need of cells engaging in neutralizing ROS 
processes. Another ART drug, efavirenz, was also reported to alter mitochondrial respiration and 
enhance ROS generation, resulting in CNS damage [255, 284-286]. Therefore, the need for novel 
therapeutic strategies that attenuate neuroinflammation and protect neurons against oxidative stress 
is immediate for DTG. Despite the higher DTG dose used in this study over those administered to 
HIV-1 infected patients the drug concentrations in brain were equivalent (Figure 4.2b). Of interest 
no significant oxidative stress increase was observed during nanoformulated DTG treatment 
compared to free DTG-injected mice. Thus, it is speculated that P407 nanoformulation could play 
a vital role in mediating ROS formation. Several other non-ionic surfactants including polyethylene 
glycol (PEG) and poloxamer 188 have shown protective effects from oxidative damage in both 
laboratory and animal models of human disease [287-290]. For example, using a guinea pig spinal 
cord injury model, it has been shown that PEG could significantly decrease injury-induced ROS 
elevation and lipid peroxidation levels [286]. A further investigation showed that PEG is not an 
effective free radical scavenger nor does it have the ability to suppress xanthine oxidase, a key 
enzyme in generating superoxide, but can significantly accelerate and enhance the healing process 




Our in vitro study suggested that surfactant poloxamer-407 could decrease the oxidative 
stress and cell damage. Thus, it is very likely that P407 has a beneficial effect on the drug efficacy 
of DTG treatment besides its role as a drug delivery system. This protective effect of non-ionic 
surfactant nanoformulations could have significant implications on future drug discovery, given 
the fact that oxidative stress is one of the most common side effects of many therapeutic drugs. 
Induction of oxidative stress can lead to drug failure in clinical trials or phase-out in the market in 
later use. Though oral ingestion of antioxidants could deem effective in counteracting such toxicity, 
it is not an ideal therapeutic solution due to their side effects or interactions with other medications 
or supplements [291-293]. Interestingly, the nanoformulated non-ionic surfactant tested in this 
study did not show any obvious toxicity in affecting brain metabolism. Previous studies have also 
found that nanoparticles can penetrate the BBB possibly via receptor-mediated endocytosis in brain 
capillary endothelial cells [294]. This suggests that another advantage of nanoformulations in 
antagonizing oxidative stress is the colocalization of nanoparticles and drug during distribution, 
resulting in possible in situ restoration of normal physiological conditions. Further investigation on 
the optimization of the material type, size, and formulation as well as its potential application for 
generic drug modification is needed. It is worth noting that oxidative stress and malformations in 
embryonic developmental including those linked to neural tube defects could occur [295-299]. 
Future works are certainly required to see if such relationships could occur between DTG and 
maternal fetal abnormalities.  
In conclusion, we examined DTG brain metabolic activities using mass spectrometry-
based metabolite profiling and observed significant dysregulation in energy and oxidative stress 
pathways; most notably, glutathione and ascorbic acid were depleted. This effect was significantly 
attenuated when DTG was administered as a nanoformulation. This data provides a possible 
pathway for the advantages of nanoformulations or other relevant therapeutic drug delivery systems 







Figure 4.1 Workflow of mouse brain global metabolomics study. Free and nanoformulated DTG 
with drug administered every other day for three total injections or by a single bolus of 45 mg/kg, 
respectively. All mice were sacrificed after 1 week following treatment. After heat fixation by 
microwave irradiation euthanasia, brain hemispheres were dissected into subregions including the 
FC, the VC, the DC, the H, and the CR. Brain subregions were extracted for untargeted LC-MS 

















Figure 4.2  Total number of dysregulated features among the FC, VC, DC, H, and CR. All the 
features were manually filtered. b DTG concentration in brain regions for free and nanoformulated 
DTG (nano-DTG) (error represents SEM and “*” represents p value < 0.05). For each experiment, 
























Figure 4.3 Glycolysis/TCA pathways and redox partners with identified metabolites. Fold 
change between free DTG and the corresponding control. Those values in circles had a p value < 
0.05. All the metabolites were identified using METLIN MS/MS fragment match and confirmed 












Figure 4.4-Fold change of metabolites indicative of oxidative stress in five different brain 
regions. Both free DTG and nanoformulated DTG treatments with their corresponding controls. 
Ascorbic acid is oxidized to threonate and GSH is oxidized to GSSG. The color scheme was 
selected to show oxidation with darker shades of red for ascorbic acid and GSH and green for 
threonate and GSSG. a Ascorbic acid and threonate fold changes for free DTG treatment. b GSH 
and GSSG fold changes for free DTG treatment. c Ascorbic acid and threonate fold changes for 
nanoformulated DTG treatment. d GSH and GSSG fold changes for nanoformulated DTG 
treatment (n = 10 samples from 5 mice). All fold changes in a and b except for H in a have p values 
< 0.05. None were found to be statistically significant in c and d. The experiments listed represent 














Figure 4.5 ROS formation and drug uptake of free and nanoformulated DTG in neurons and 
MDM cultures. a, b ROS fold change of neurons and MDM relative to their respective controls, 
respectively (error represent SEMand “*” represents p value < 0.01). c, d ROS levels after TBHP 
challenge in the neurons and MDM treated with free DTG, nanoformulated DTG, and their 
respective vehicle controls with a series of dilution from 10 to 100 μM. The data was normalized 
with TBHP-positive control (10 μM). e, f DTG concentration in neurons and MDM respectively 
treated with free DTG and nanoformulated DTG. The DTG concentration in neurons treated with 
100 μM free DTG equals the DTG concentration treated with 10 μM nanoformulated DTG (dotted 



















Figure 4.6.  Relative abundance of oxidative stress biomarkers. (a) ascorbic acid; (b) threonate; 
(c) glutathione (GSH); (d) GSH/GSSG ratio in five dissected regions, frontal cortex, ventral cortex, 
dorsal cortex, hippocampus and cerebellum (n=10 samples from 5 mice) from mice treated with 
free DTG and Nano-DTG compared with their respective controls. All data corresponds to global 
metabolomics analysis. Error bars represents standard error of the mean. “*” and “**” represents p 












Figure 4.7. Free DTG and nanoformualted DTG (Nano-DTG) reactive oxygen species (ROS) 
formation in murine neurons and human monocyte derived macrophage (MDM) cells 24 
hours post treatment. (a) Neurons and (b) MDM treated with 10 µM TBHP (positive control), 
free DTG (100 and 500 µM), Nano-DTG (100 and 500 µM), and their respective vehicle controls. 

























1 2 0 0
F re e  D T G  C o n tro l (1 0 0 M )
C e lls
T B H P
F re e  D T G  C o n tro l (5 0 0 M )
F re e  D T G  (1 0 0 M )
F re e  D T G  (5 0 0
M )
N a n o -D T G  C o n tro l (1 0 0 M )
N a n o -D T G  C o n tro l (5 0 0 M )
N a n o -D T G  (1 0 0 M )
N a n o -D T G  (5 0 0 M )
D a y  1 _ M D M
D a y  1 _ N e u ro n s














5 0 0 0
1 0 0 0 0
1 4 0 0 0
1 6 0 0 0
1 8 0 0 0
2 0 0 0 0 C e lls
T B H P
F re e  D T G  C o n tro l (1 0 0 M )
F re e  D T G  C o n tro l (5 0 0 M )
F re e  D T G  (1 0 0 M )
F re e  D T G  (5 0 0 M )
N a n o -D T G  C o n tro l (1 0 0 M )
N a n o -D T G  C o n tro l (5 0 0 M )
N a n o -D T G  (1 0 0 M )
N a n o -D T G  (5 0 0 M )
D a y  1 _ N e u ro n s














5 0 0 0
1 0 0 0 0
1 4 0 0 0
1 6 0 0 0
1 8 0 0 0
2 0 0 0 0 C e lls
T B H P
F re e  D T G  C o n tro l (1 0 0 M )
F re e  D T G  C o n tro l (5 0 0 M )
F re e  D T G  (1 0 0 M )
F re e  D T G  (5 0 0 M )
N a n o -D T G  C o n tro l (1 0 0 M )
N a n o -D T G  C o n tro l (5 0 0 M )
N a n o -D T G  (1 0 0 M )
N a n o -D T G  (5 0 0 M )
D a y  1 _ N e u ro n s














5 0 0 0
1 0 0 0 0
1 4 0 0 0
1 6 0 0 0
1 8 0 0 0
2 0 0 0 0 C e lls
T B H P
F re e  D T G  C o n tro l (1 0 0 M )
l 5
F re e  D T G  (1 0 0 M )
F re e  D T G  (5 0 0 M )
N a n o -D T G  C o n tro l (1 0 0 M )
l 5
N a n o -D T G  (1 0 0 M )
N a n o -D T G  (5 0 0 M )
D a y  1 _ N e u ro n s













5 0 0 0




2 0 0 0 0 C e lls
T B H P
F re e  D T G  C o n tro l (1 0 0 M )
F re e  T  o n tro l (5 0 0  )
F re e  D T G  (1 0 0 M )
F re e  D T G  (5 0 0 M )
N a n o -D T G  C o n tro l (1 0 0 M )
N a n o -D T G  C o n tro l (5 0 0 M )
N a n o -D T G  (1 0 0 M )
N a n o -D T G  (5 0 0 M )
D a y  1 _ N e u ro n s














5 0 0 0




2 0 0 0 0 C e lls
T B H P
F re e  D T G  C o n tro l (1 0 0 M )
r   tr l (5 )
F re e  D T G  (1 0 0 M )
F re e  D T G  (5 0 0 M )
N a n o -D T G  C o n tro l (1 0 0 M )
5
N a n o -D T G  (1 0 0 M )
N a n o -D T G  (5 0 0 M )
D a y  1 _ N e u ro n s














1 0 0 0 0
1 4 0 0 0
1 6 0 0 0
1 8 0 0 0
2 0 0 0 0 C e lls
T B H P
F re e  D T G  C o n tro l (1 0 0 M )
F re e  D T G  C o n tro l (5 0 0 M )
F re e  D T G  (1 0 0 M )
F re e  D T G  (5 0 0 M )
N a n o -D T G  C o n tro l (1 0 0 M )
N a n o -D T G  C o n tro l (5 0 0 M )
N a n o -D T G  (1 0 0 M )
N a n o -D T G  (5 0 0 M )
D a y  1 _ N e u ro n s














5 0 0 0
1 0 0 0 0
1 4 0 0 0
1 6 0 0 0
1 8 0 0 0
2 0 0 0 0 C e lls
T B H P
F re e  D T G  C o n tro l (1 0 0 M )
F re e  D T G  C o n tro l (5 0 0 M )
F re e  D T G  (1 0 0 M )
F re e  D T G  (5 0 0 M )
N a n o -D T G  C o n tro l (1 0 0 M )
N a n o -D T G  C o n tro l (5 0 0 M )
N a n o -D T G  (1 0 0 M )
N a n o -D T G  (5 0 0 M )
D a y  1 _ N e u ro n s














5 0 0 0
1 0 0 0 0
1 4 0 0 0
1 6 0 0 0
1 8 0 0 0
2 0 0 0 0 C e lls
T B H P
F re e  D T G  C o n tro l (1 0 0 M )
l 5
F re e  D T G  (1 0 0 M )
F re e  D T G  (5 0 0 M )
N a n o -D T G  C o n tro l (1 0 0 M )
l 5
N a n o -D T G  (1 0 0 M )
N a n o -D T G  (5 0 0 M )
D a y  1 _ N e u ro n s













5 0 0 0




2 0 0 0 0 C e lls
T B H P
F re e  D T G  C o n tro l (1 0 0 M )
F re e  T  o n tro l (5 0 0  )
F re e  D T G  (1 0 0 M )
F re e  D T G  (5 0 0 M )
N a n o -D T G  C o n tro l (1 0 0 M )
N a n o -D T G  C o n tro l (5 0 0 M )
N a n o -D T G  (1 0 0 M )
N a n o -D T G  (5 0 0 M )
D a y  1 _ N e u ro n s














5 0 0 0




2 0 0 0 0 C e lls
T B H P
F re e  D T G  C o n tro l (1 0 0 M )
r   tr l (5 )
F re e  D T G  (1 0 0 M )
F re e  D T G  (5 0 0 M )
N a n o -D T G  C o n tro l (1 0 0 M )
5
N a n o -D T G  (1 0 0 M )
N a n o -D T G  (5 0 0 M )
D a y  1 _ N e u ro n s














1 0 0 0 0
1 4 0 0 0
1 6 0 0 0
1 8 0 0 0
2 0 0 0 0 C e lls
T B H P
F re e  D T G  C o n tro l (1 0 0 M )
F re e  D T G  C o n tro l (5 0 0 M )
F re e  D T G  (1 0 0 M )
F re e  D T G  (5 0 0 M )
N a n o -D T G  C o n tro l (1 0 0 M )
N a n o -D T G  C o n tro l (5 0 0 M )
N a n o -D T G  (1 0 0 M )































5.1 Summary and conclusions  
 The successful development of combination antiretroviral therapy for the treatment of 
HIV-1 undoubtably changed the course of human history, as millions of infected people can now 
anticipate a prolonged lifespan instead of a certain and painful death. However, the persistence of 
virus and the continued strain of the pandemic on global healthcare has resulted in HIV-1 research 
to develop novel strategies to improve upon current antiretroviral therapy. Improvements in 
pharmacodynamic and pharmacokinetic profiles have shown remarkable promise in increasing 
drug adherence, reducing secondary toxicities, and preventing new infections. Our lab has shown 
that the enhancement of the hydrophobicity of current ARVs via nanocrystals incased in 
biodegradable polymers allows for the establishment of drug depots within monocyte-
macrophages, significantly prolonging drug half-life. But experimentation of such 
nanoformulations within animal models has proved cumbersome, with biodistribution 
measurements extending weeks or even months proving particularly tedious.  
 The first study (chapters 2 and 3) assessed the use of our theranostic nanoparticle platform 
and its ability to accumulate within monocyte-macrophages as well as reticuloendothelial tissues. 
Theranostic nanotechnology has allowed the rapid screening of drug tissue biodistribution and 
pharmacokinetics which allows for pharmacodynamic improvements. Our theranostic nanoparticle 
platform was developed with careful consideration of components that allowed assessment of 
particle presence as well as component concentration within cells and tissues in vitro, in vivo, and 
ex vivo. Encasement of hydrophobic ARVs and imaging contrast agents within a single 
nanoformulation produced theranostic nanoparticles with a multitude of modalities, allowing for 
validations of the multiple measurements performed. Incorporation of Eu3+ into the nanoparticles 
allowed for confirmation of particle presence within cells and tissues via fluorescence confocal 
imaging. Cobalt ferrite provided a paramagnetic material necessary for T2 contrast in MR imaging. 




biodistribution and activity that would otherwise not be possible with traditional plasma post-
mortem tissue concentration analysis.  Upon synthesis, EuCF-DTG nanoparticles showed 
remarkably consistent size, size, magnetism, fluorescence, and proper ARV drug loading as well 
as drug release in PBS.  Administration of EuCF-DTG to in vitro macrophage cell culture resulted 
in consistent cellular uptake of nanoparticles, with FA targeted EuCF-DTG showing significantly 
higher uptake. Uptake of EuCF-DTG nanoparticles did not affect cellular viability in these studies. 
Furthermore, confocal microscopy of in vitro macrophages displayed EuCF-DTG nanoparticles 
localizing within subcellular components, with a high proportion of nanoparticles residing within 
recycling endosomes. Perhaps most importantly, EuCF-DTG nanoparticles exhibited antiretroviral 
activity upon administration to HIV-1 infected in vitro cellular cultures, confirming the therapeutic 
effects of our theranostic nanoparticle platform.  Real time in vivo MR imaging of rats administered 
EuCF-DTG nanoparticles both via IV and IM injection confirmed nanoparticle presence within 
reticuloendothelial tissues at 2, 5, and 10 days post-injection. Quantification of iron concentrations 
within liver and spleen was performed by MRI T2 mapping with IV injected animals exhibiting a  
two-fold increase in iron compared to IM injected animals. Post-mortem tissue concentrations of 
cobalt and DTG were measured by ICP-MS and UPLC- MS/MS, respectively. DTG and cobalt 
levels following IM or IV injection of nanoparticles showed coordinate tissue and plasm drug and 
cobalt levels. Furthermore, MRI iron concentrations performed in vivo were validated by ex vivo 
concentrations of cobalt and DTG. Overall, such data suggests that the amount of drug that 
accumulates in tissues can be estimated in real time by in vivo MRI by using the known signal-to-
drug ratio of EuCF-DTG nanoparticles. Post-mortem tissue confocal microscopy confirmed the 
presence of EuCF-DTG nanoparticle within recycling endosomal compartments in macrophages, 
mirroring results found in in vitro confocal microscopy studies. Additional biodistribution studies 
were performed by EuCF-DTG administration to rhesus macaques. Highest concentrations of DTG 




lymph nodes. These results suggest that EuCF-DTG nanoparticles are taken up by macrophages in 
reticuloendothelial tissues in rhesus macaques, similar to biodistribution studies performed in rats.  
 Our second study (chapter 4) assessed the possibility that native ARV drug administration 
could cause neurotoxicity and whether administration of ARV drug as a nanoformulation could 
attenuate any observable neurotoxic effect. While ART restricts HIV-1 replication and 
subsequently improves the quality and longevity of life for infected people, such treatment can lead 
to adverse clinical outcomes such as drug resistance and systemic adverse events. Both could be 
affected by long-acting slow effect release ART. Indeed, maintenance of sustained plasma drug 
levels, for weeks or months, after a single-high level dosing, could improve regimen adherence but 
additionally affect systemic toxicities, including those of the CNS. To address this a potent and 
durable HIV-1 integrase inhibitor used effectively in combination ART was tested. Rodents were 
administered parenteral 45-mg/kg doses. DTG-associated changes in CNS homeostasis were 
assessed by measuring brain metabolic activities. After antiretroviral treatment, brain subregions 
were dissected and screened by mass spectrometry-based metabolomics. Metabolic drug-related 
dysregulation of energy and oxidative stress were readily observed within the cerebellum and 
frontal cortex following native drug administrations. Each was associated with alterations in neural 
homeostasis and depleted canonical oxidation protection pools that included glutathione and 
ascorbic acid. Surprisingly, the oxidative stress-related metabolites were completely attenuated 
when DTG was administered as nanoformulations. These data demonstrate the importance of 
formulation design in control of DTG or perhaps other antiretroviral drug-associated CNS events. 
 Overall, the data presented in this thesis will have significant impact on research striving 
for both the care for HIV-1 patients and the eradication of the virus. A theranostic nanoparticle 
platform was designed specifically for HIV-1 therapeutic innovation, allowing for improvements 
in pharmacokinetic and biodistribution profiles of LASER ART technology within a relatively 




that has been applied for HIV-1 research. Furthermore, investigation of possible off target 
neurological effects of relatively new ARV medications allows for improvements in patient care. 
The attenuation of the observed changes in the neuro-metabolome by nanoformulated ARV is 
representative of such improvements. Such nanoformulated ARV not only has a longer half-life 
and improved biodistribution, but it’s slower systemic release can possibly prevent neurological 
side-effects of the drug. Both projects have potential for dramatic influence on future directions of 
HIV research.   
5.2 Limitations 
While the HIV-1 theranostic technology that was developed and experimentally tested 
ultimately met our goals that are outlined within this thesis, several limitations of such 
nanotechnology exist. Future development and utilization of HIV-1 theranostic nanotechnology 
must take note of such limitations and make efforts to overcome them.  
A major limitation of our EuCF-DTG theranostic nanoparticle platform was that of drug 
loading. Indeed, the ability to load adequate amounts of drug into a nanoscale system while still 
containing the necessary contrast agents and fluorescent components is particularly challenging.  
EuCF-DTG nanoparticles exhibited a drug loading percentage of ~6.2% weight/weight; while such 
concentrations were adequate to exhibit antiretroviral activity in vitro, it is unlikely that such drug 
levels would have much of a therapeutic effect on HIV-1 replication in vivo. Specifically, 
biodistribution studies of EuCF-DTG nanoparticles performed on SIV-1 infected rhesus macaques 
confirmed this issue. While the presence of the nanoparticle component cobalt and the ARV DTG 
were confirmed within the plasma and multiple tissue sites, SIV-1 viremia within these same tissues 
did not show any differences between pre and post injection of EuCF-DTG nanoparticles. Such 
data exhibits that EuCF-DTG being delivered to tissue sites of viral replication and that DTG is 
being released, but that DTG levels are not adequate to reduce SIV-1 viremia. Diagnostic 




imaging modality. While MRI is a powerful diagnostic tool with superior spatial resolution, it has 
difficulty imaging particular tissues that are relevant to HIV-1 pathology. Specifically, T2 weighted 
MR images of tissues or organs containing air, such as the lungs or gastrointestinal tract, cannot be 
performed to very low signal-to-noise ratios in such areas. This is a major limitation due to the gut 
associated lymphoid tract being a significant HIV-1 reservoir, in which theranostic nanoparticle 
deliverance and subsequent MR imaging would be beneficial. Furthermore, MRI has difficulty 
differentiating small lymphoid tissues, such as lymph nodes, from the surrounding tissues. The 
inability to image and quantify theranostic nanoparticle concentrations within such tissues is a 
major limitation.  
Metabolomic analysis of the brains of native DTG and nanoformulated DTG administered 
mice are limited as it is difficult to ascertain whether metabolic changes in redox metabolites is 
truly indicative of HIV-1 associated neurocognitive disorders. Indeed, while the changes that were 
exhibited can be classified as neurotoxic, alterations in neuronal homeostasis and depletions of 
canonical oxidation protection pools might not result in the manifestation of neuropsychiatric 
events. This is characteristic of the majority of psychiatric or neurological studies that utilize animal 
models; presentation of adverse behaviors or psychiatric abnormalities is often nuanced and 
requires complex questioning between the patient and clinician. Such psychiatric evaluation is not 
possible in animals. Deviation from normal baseline behavior, or abnormalities in post-mortem 
tissue analysis in comparison to control animals are the only way to establish possible adverse 
neuropsychiatric events. The animals utilized in our second study (chapter 4) did not display any 
abnormal behaviors during their administration of native or nanoformulated DTG.  
5.3 Future Directions 
 Potential future applications of HIV-1 theranostic technology are both diverse and exciting. 
Successful establishment of a theranostic nanoparticle platform allows for rapid assessment of 




targeting schemes for HIV-1 eradication to be evaluated more efficiently. Experimentation that 
would take months or years with traditional pharmacokinetic evaluations can be performed within 
weeks using a theranostic platform, allowing more time and resources to be put towards more 
innovative nanotechnological developments. Additionally, further refinement of theranostic 
nanoparticles is a future possibility. Addition of a radionucleotide into the nanoparticle system 
allows for another imaging modality; such a theranostic platform would allow for MRI, 
fluorescence, and PET/SPECT imaging.   Radio-imaging of nanoparticles allows for biodistribution 
analysis within tissues that are not possible with MRI. Alterations in nanoparticle components and 
size could lead to specific targeting of other HIV-1 reservoirs, such as the brain or lymphoid 
systems. Furthermore, magnetic movement of magnetically sensitive nanoparticles into areas of 
interest via external magnetic gradients could have significant potential in drug delivery 
technology, both in HIV-1 and other diseases. All future directions give optimism to the eventual 
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